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ABSTRACT 
 Sickle cell disease (SCD) is a monogenic disorder with multi-organ 
involvement(1). Patients with SCD suffer from recurrent vaso-occlusive crisis 
(VOC) resulting from sickling of red blood cells, which is induced by 
polymerization of deoxy-sickle hemoglobin (HbS)(1,2). Fetal hemoglobin (HbF) can 
ameliorate symptoms of SCD by inhibiting deoxy-HbS polymerization(3). 
Hydroxyurea (HU) is approved by FDA for the treatment of SCD(4). It induces 
HbF synthesis through multifactorial and still not well understood mechanisms(4-
7). However, approximately 5-15% of patients show no significant clinical 
improvement(8). Additionally, numerous patient and physician-related factors limit 
its utilization(9). Therefore, it is important to identify additional HbF-inducing 
therapeutic agents, particularly those that act by mechanisms different from HU 
to allow potential combination therapy in the future. Previously, peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) was shown 




erythroid progenitors obtained from Lin- cells from SCD transgenic mice induces 
γ-globin expression(10), suggesting that PGC-1α represents a new molecular 
target for potential therapeutic intervention in treating SCD.  
In the present study, the effect of PGC-1α upregulation in primary human 
CD34+ derived erythroid cells was explored; an increase in γ-globin mRNA and 
the percent of F-cells was observed. Through literature search, ZLN005 and SR-
18292 were identified as potential PGC-1α agonists(11,12). Both compounds 
increase the percentage of F-cells in primary human CD34+ derived erythroid cell 
culture. Combined treatment with HU led to a significantly higher increase in F-
cell % than the increase observed under treatment with either HU, ZLN005 or 
SR-18292 alone. Results from those studies add to the understanding of PGC-1α 
and its effects on primary human erythroid cell differentiation, maturation, and 
HbF induction. Additionally, the results show proof of principle for combination 
therapy to treat SCD patients to ameliorate their disease severity by up-
regulating HbF expression. Together, the knowledge gained through these 
studies is novel and will potentiate the development of a new class of compounds 
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CHAPTER I: Introduction 
1.1 Red blood cells 
Red blood cells (RBCs) or erythrocytes are enucleated cells in the 
peripheral blood circulation. They contain hemoglobin which is a heme-
containing protein capable of binding oxygen in the lung and delivering it to 
tissues. Their average life span in normal adults ranges between 100 and 120 
days(13). In healthy individuals, erythrocytes are produced in the bone marrow of 
the axial skeleton in a process known as erythropoiesis(13).  
 
1.1.1 Erythropoiesis 
A normal individual generates 2 million RBCs every second(14). 
Erythropoiesis is complex and tightly regulated(14-16). The process involves a 
sequence of cellular differentiation stages(14,17). It begins with hematopoietic stem 
cells (HSCs) and progenitor cells (HPCs), cell types that possess the ability to 
self-renew and have multipotent differentiation capacity, respectively(14-16). Figure 
1.1 depicts the development of erythrocytes from HSCs to enucleated cells(17). 
Erythroid differentiation from HSCs can be divided into 3 phases(14).  
The first phase of erythroid differentiation is called the engagement phase; 
there are two models in this phase(13,14,18); the classical model is where HSCs 
differentiate into more committed erythroid progenitors; common myeloid 
progenitor (CMP), then the megakaryocytic-erythroid progenitor (MEP) and finally 




into colony forming unit-erythroid (CFU-E)(14,18). The alternative model state that 
megakaryocytic-erythroid progenitor can directly differentiate from HSCs(13,15,18,19) 
(Figure 1.1). 
The second phase involves the differentiation of CFU-E to form 
proerythroblasts to basophilic, polychromatophilic, orthochromatic erythroblasts 
and lastly, reticulocytes(14,15,18). This phase is characterized by the gradual 
accumulation of hemoglobin and progressive decrease of cell size and nuclear 
condensation that results in enucleation and formation of reticulocytes(14).  
The final phase involves the maturation reticulocyte into erythrocytes. 
During this phase, the erythrocytes acquire a biconcave shape through 
membrane remodeling(14). Erythroid differentiation in adults occurs in bone 
marrow niches known as erythroblastic islands(13,14). A bone marrow niche 
consists of a central macrophage surrounded by up to 30 erythroid cells at 
various stages of maturation(13,14). Macrophages in erythroblastic islands help 
regulate the rate of erythropoiesis by a positive and negative feedback 
mechanism(14). For example, macrophages secrete insulin-like growth factor-1 
that promotes erythroid proliferation and maturation(14). Additionally, these 
macrophages phagocytize extruded nuclei and they modulate the transfer of iron 
for heme synthesis in erythroid progenitors(13,14).  
 
3 
Figure 1.1. Erythropoiesis.  
A simplified diagram of erythropoiesis depicting the markers expressed in each 
cell type. The color intensity represents the expression level (lighter color, lower 
expression; darker color, higher expression). (Adapted and redrawn from Marci 





 Heme, α- and β-globin chains are key components, in an appropriate 
stoichiometry, to form hemoglobin molecules(20). Heme is an iron-containing 
compound important for respiratory cytochromes in mitochondria. Approximately 
80–90% of heme synthesized in erythroid cells is incorporated into 
hemoglobin(21). Heme biosynthesis is controlled by the rate-limited enzyme 5-
aminolevulinate synthase (ALAS)(20). There are two isozymes of ALAS, one of 
which is ubiquitously expressed and encoded by ALAS1 (Chr. 3p21.2)(22). The 
other is an erythrocyte-specific isoform encoded by ALAS2 (Chr. Xp11.21)(20). 
Mutation in ALAS2 causes X-linked pyridoxine-responsive sideroblastic anemia, 
whereas a defect in ALAS1 is associated with porphyria(22).  
 
1.1.2.1 Globin chain compositions 
Hemoglobin is a tetrameric protein(23). A single molecule of hemoglobin 
has two pairs of globin chains (2 α-globin chains and 2 β-globin chains) that are 
very closely related and formed by pairing of a dimer of polypeptide chains(23). 
Each globin within these chains has one heme moiety(23). Therefore, each 






1.1.2.2 Functions of hemoglobin 
Hemoglobin has multiple functions: 1) Transporting oxygen to tissues, 
mostly for the mitochondrial oxidative phosphorylation(25) and transporting carbon 
dioxide from tissues to the lungs; 2) Buffering the hydrogen ions formed inside 
the erythrocytes from the conversion of carbon dioxide into bicarbonate(25); 3) 
Nitric oxide (NO) metabolism and transport. Under physiological conditions, 
RBCs are kept in the center of the vessel due to blood flow; this leads to a cell-
free zone that limits the interaction between endothelially produced NO and 
hemoglobin inside the RBC(26). Additionally, the RBCs membrane creates a 
barrier that slows down the reaction of NO with hemoglobin(26). During disease 
conditions, for example, intravascular hemolysis, these barriers are disrupted as 
hemoglobin is released from the RBCs into the blood circulation and into the cell-
free zone where it can interact with NO(26) (more details about NO 
pathophysiology are discussed in Section 1.2.5.5).  
NO reacts with oxyhemoglobin to produce methemoglobin (Fe+3); this 
reaction is reversed by the erythrocyte methemoglobin reductase system(23). 
Additionally, NO reacts with deoxyhemoglobin to form nitrosyl-hemoglobin (NO-
hemoglobin)(23). It is thought that the circulating NO-hemoglobin is capable of 
releasing NO molecules and, therefore, indicates a potential mechanism of 
hemoglobin-based like transport of NO(23). Also, NO can bind β-chain amino acid 
number 93, cysteine, under oxygenated condition to form S-nitrosyl-hemoglobin 




oxygen concentration(23). Nevertheless, this hypothesis is controversial(23,26) and 
the role of hemoglobin in NO transport is still not fully understood(26). 
 
1.1.2.3 Globin genetic structure and development 
Globins are divided into two families (Figure 1.2 A). The α-like globin 
genes (ζ, α1, and α2) are located on chromosome 16. HS-40, an erythroid-
specific DNAse-I-hypersensitive site (HS), is a major regulatory element for the 
α-globin cluster(27). Beta-like globin genes (ε, γ, δ, and β) are located on 
chromosome 11. The locus control region (LCR) in the β-globin cluster is a major 
regulatory region composed of five HS elements at the 5ʹ end(27). Each globin 
gene is expressed in a specific period (Figure 1.2 B). Hemoglobin synthesis 
starts in the first week of embryonic development(28). In the yolk sac, embryonic 
hemoglobin; Hb Grower 1, Hb Grower 2, and Hb Portland are expressed during 
the first few weeks of gestation(23,28-32). Around weeks 6–10, hemoglobin 
production begins in the fetal liver, ζ-globin and ε-globin expression declines, α 
and γ globin expression increases, and fetal hemoglobin (HbF) synthesis begins. 
HbF is a heterogeneous mixture of γ-globin genes (HBG1 and HBG2) products; it 
can contain glycine (Gγ) or alanine (Aγ) at amino acid position 136(23). At birth, 
glycine-containing γ-globin is predominant, but after birth, the alanine-containing 
γ-globin replaces the glycine-containing γ-globin(28,29). During the third trimester, 
the site of erythropoiesis and hemoglobin synthesis is gradually shifted to the 




and HbA1, respectively, replacing HbF(23). HbA1 composed of 2 α- and 2 β-globin 
chains accounts for up to 97% of all hemoglobin molecules in adults (23). HbF and 
HbA2 represent 1% and 2%, respectively, of all hemoglobin in adults(15,23).  
Figure 1.2. Normal human globin gene clusters and switch.  
Hemoglobin is a tetramer with an iron-containing molecule (heme) binding four 
globin molecules together. In general, the globin part consists of two pairs of 
polypeptide subunits, and each pair is encoded by a family of genes. A) Alpha-
like globin genes (functional genes ζ, α1, and α2) are located on chromosome 




11. B) Each globin gene is expressed at a specific time and they are arranged 
from 5ʹ to 3ʹ according to their order of expression. (Adopted and redrawn from 
Higgs et al., 2012(27)). 
 
1.1.2.4 Hemoglobin disorders 
Hemoglobin disorders are mostly inherited in an autosomal recessive 
manner(33) and can generally be classified into two main categories; reduced 
globin chain synthesis or synthesis of abnormal globin chain variants(27,33,34). 
Reduced globin synthesis is termed thalassemia(27,33,34). The production of α- and 
β- globin should closely match; the imbalance in these submits’ production is the 
central pathophysiology of thalassemia(27). In β-thalassemia (reduced or absent 
production of β-globin), the presence of free unbound α-globin subunits form 
insoluble aggregates that are toxic to the erythrocyte(34). In α-thalassemia 
(reduced production of α-globin), excess β-globin form hemoglobin H, a soluble 
tetramer, that is unstable and form inclusion bodies that damage the erythrocyte 
and shorten their life span(34). The complete absence of α-thalassemia leads to a 
condition called hydrops fetalis with hemoglobin Bart’s (4 γ-globin chains 
tetramer that has a very high oxygen affinity)(33,34). The other group of 
hemoglobin disorders is characterized by the production of abnormal hemoglobin 
structure(34). Hemoglobin S (HbS) is one example of this group of hemoglobin 
disorders(34) and will be discussed in more detail later (section 1.2). Some globin 




for example, a mutation in the β-globin that alters the binding site for 2,3 
Diphosphoglycerate (2,3 DPG) will change the hemoglobin oxygen affinity(34).  
 
1.2 Sickle cell disease 
1.2.1 Genetic abnormality 
Sickle cell disease (SCD) is identified as a group of autosomal recessive 
disorders termed hemoglobinopathies(2,35). A missense mutation (GAG to GTG) 
leads to the substitution of the polar amino acid, glutamic acid, by a non-polar, 
hydrophobic valine in the 6th amino acid position of the -globin chain(1,2,36-40). 
(However, in the amino acid numbering for protein revised convention, it is the 
seventh codon, HBB glu7val, which includes the cleaved initiator methionine 
residue(39)). This produces abnormal hemoglobin termed hemoglobin S 
(HbS)(1,2,37,39,41). It is important to recognize that sickle cell anemia (SCA), the 
most prevalent genotype of SCD, is a term used exclusively for the homozygous 
hemoglobin S (HbSS) genotype(37), while the term SCD includes other 
heterozygous genotype conditions identified as hemoglobin SC disease (HbSC 
disease), hemoglobin S-beta zero thalassemia (HbS-β0 thalassemia), and 
hemoglobin S-beta plus thalassemia (HbS-β+ thalassemia)(42); these genotypes 
will be discussed later (section 1.2.4).  
SCD was discovered in 1910 by Dr. James B. Herrick, who observed the 
presence of sickle-shaped RBCs in the blood of a young man complaining of 




1910, more details about its pathophysiology and symptoms were discovered in 
the 1940s and 1950s by Pauling and his colleagues(1,43,44). They determined that 
this disease was genetically inherited and that HbS had entirely different 
chemical characteristics than HbA(1,43,44). As a result, the term “molecular 
disease” was used for disorders resulting from proteins with an abnormal 
chemical representation(44).  
In the 1960s, Vernon Ingram determined that HbS is formed from a 
mutation in the sixth codon of HBB(43,45) (In the amino acid numbering for protein 
revised convention, it is the seventh codon of the HBB(39)). Since then, more 
optimized tests have been utilized for the detection of SCD, and treatments for 
the complications of SCD have been developed(41,43). Genetic counseling has 
emerged as an essential instrument for informing individuals about the possibility 
of having a child with SCD(46). Due to comprehensive care, such as the use of 
penicillin for children below the age of 5 years old(35) and transcranial Doppler 
screening for stroke risk(35), the life expectancy of children born with SCD has 
increased(47). In the US, more than 90% of children with SCD live to adulthood(47). 
Nevertheless, the median survival age for SCA remains in the 40s and 50s(48-50). 
 
1.2.2 Epidemiology of sickle cell disease 
 The HbS allele was originally distributed over sub-Saharan Africa, the 
Middle East, the Mediterranean and India(35). This wide distribution of the HbS 




relative protection against Plasmodium falciparum malaria(35,40). Several studies 
have verified the abnormal transportation of the Plasmodium falciparum and the 
lower parasite densities in those carrier individuals(35). Individuals with HbAS are 
90% less susceptible to experience severe malaria than individuals with HbAA(2). 
Therefore, SCD is more prevalent in parts of the world where malaria is 
historically endemic(51). Population movements led to a much wider distribution of 
the HbS allele especially in North America and Western Europe(2,35).  
SCD affects millions of people worldwide, affecting approximately 300,000 
births of babies with SCD per year(35,52). It is considered to be one of the most 
common inherited blood disorders in the United States, where 1 in 12 African 
Americans is identified as a carrier of the disorder(53). The number of patients 
with SCD in the United States is approximately 100,000 and will most likely 
increase over time.  
Around 90% of the worldwide SCD population resides in Nigeria, India, 
and the Democratic Republic of Congo(54). In these countries, the disease is 
found in up to 2% of the population and the sickle cell trait (SCT) prevalence is 
as high as 30%. It is estimated that at least 150,000 births with SCD occur 
annually in Nigeria alone(54). In the state of Chhattisgarh, India, SCT prevalence 
is reported as 9.84% and SCD is 0.37%(55). 
Other countries with a high prevalence of SCD include Italy, Brazil and 
Middle Eastern Arab countries. The increased prevalence in Italy has been 




settling in Italy. The highest frequency of SCT in Italy (reportedly as high as 13%) 
has been observed in the region of Sicily(56). In Brazil, the prevalence of SCT is 
highest in the northeast region (10%)(57). In Oman, approximately 6% of the 
population have SCT and 0.2% have SCD(58,59).  
In Saudi Arabia, SCD is a common genetic disorder with a prevalence of 
24-106 per 10,000 and is concentrated in the Eastern and South Western 
Provinces(60). In the Eastern Province, the prevalence of SCD is 1 in 69(61). Owing 
to a high rate of consanguinity in Saudi Arabia, ranging from 50-57% (62,63), 
recessive traits are more likely to be expressed(4). This is a key limitation for 
estimating the allele and carrier frequencies using Hardy-Weinberg equilibrium. 
However, the percentage of consanguinity reported was based on national 
figures, whereas the data for the Eastern Province came from a single region. 
Different regions in the Eastern Province have different cultures and rates of 
consanguineous marriage. In one study, the prevalence of SCA in the Qatif and 
Al‐Hasa regions in the Eastern Province was found to be 1/42.6 and 1/92.6, 
respectively(64). This was a hospital-based study and did not represent the entire 
province(64). The allele frequency of SCA in the Eastern Province of Saudi Arabia 
may not have been accurately estimated, and many factors such as 
consanguinity may have played a role in preventing it from being accurately 
calculated. However, the prevalence of SCD in the Eastern Province is very high 




In this context, SCA is inherited in an autosomal recessive manner. A 
baby born with SCA inherits a gene for the disease from both parents. In the 
event that both parents are heterozygous for the SCA mutation (βA/βS), also 
known as SCT, there is at least a 25% probability that each of their children will 
inherit SCA(53). The probability that the child will inherit only one copy of the 
defective gene is 50%. It is important to note that individuals who only carry the 
SCT do not develop SCA. Nevertheless, there is a risk that such carriers of the 
disease may transmit the defective gene to their children(43). In addition, SCT 
may have certain health risks, as summarized in Table 1.1. That is why 


























A decline in 
kidney 
function 
Hyposthenuria; inability to concentrate urine.  
An absence of access to water can lead to 
dehydration. 
(1,65) 
A decline in the estimated glomerular filtration 
rate (eGFR) due to renal medullary damage 
over time. The exact mechanism of this 




Splenic infarcts can occur in SCT if the 
individual is exposed to hypoxic conditions at 






Cohort studies have identified SCT as a risk 
factor for venous thromboembolism. The 




related death  
 
This is a rare event. It was observed among 
athletes with SCT. In US-college athletes with 
SCT, the risk of exercise-related death was 
15 times higher than in athletes without SCT. 
The mechanism is not precisely clear, but it 
has been suggested that rhabdomyolysis 





A difference in exercise tolerance and 
pulmonary function were observed when 
comparing SCT with matched control of non-
carriers. This observation was at sea level as 
well as high altitudes 
(72) 




1.2.3 Natural history of sickle cell disease  
Newborns with SCD do not develop symptoms owing to the high HbF 
levels. However, HbF is gradually replaced by HbS; this substitution occurs at 
different rates among patients(49). In some, HbS levels may reach a pathological 
level as early as 10 weeks of age(49). As the child gets older, more complications 
emerge(49). Clinical complications of SCD vary in severity among the SCD 
variants (discussed in section 1.2.4) and can be divided into acute and chronic 
complications.  
 
1.2.3.1 Acute complications 
Vaso-occlusive crises (VOC): They are also known as painful crises(73) 
the most common complication, cause for emergency department visits and 
hospitalization in SCD(1,2,35,37). Painful crises are unpredictable and may be 
triggered by dehydration, infection, cold, stress, acidosis, hypoxia, and pain 
itself(35). The first episode of vaso-occlusive crises can happen in infancy, 
presenting with dactylitis which is caused by vasoocclusion in the bone marrow in 
the small bones of the hands and feet(5,49). The pathophysiology of vaso-
occlusive crises will be discussed later (section 1.2.5.3). 
Infection: Infection is a major cause of morbidity and mortality for young 
children with SCD, owing to hyposplenism or asplenia that develops in early 
childhood(35,49). In addition, impaired fixation of complement, reduced oxidative 




antibody responses that lead to defective opsonization, all contribute to an 
increased susceptibility for infection(35,49). Therefore, children with SCD are at risk 
of infection with encapsulated organisms (surrounded by polysaccharides) such 
as Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria 
meningitidis(35). The routine use of prophylactic penicillin and vaccination in 
children below 5 years of age has greatly reduced the incidence of these 
infections(5,35,73). Viral infection can be severe in individuals with SCD(49). For 
example, Parvovirus B19 infection can destroy erythroid precursors in the bone 
marrow for a period of 8–10 days, causing a transient cessation of erythropoiesis 
(referred to as aplastic crisis) until the immune system starts producing the 
specific IgG to neutralize parvovirus(49,73). In healthy individuals, such an infection 
may produce negligible symptoms owing to the 120-day life span of normal 
RBCs(49). In contrast, in patients with SCD, this infection can lead to life-
threatening anemia owing to the shorter life span of sickled RBCs (10–20 
days)(49). Additionally, parent and patient education is essential; medical attention 
should be sought when patients with SCD have an elevated temperature higher 
than 102°F, and it should be dealt with as a medical emergency(73). 
Acute chest syndrome: Acute chest syndrome (ACS) is characterized by 
the presence of a new infiltrate on chest radiograph involving at least one 
segment of the lung, accompanied by fever, chest pain, cough, shortness of 
breath, or wheezing(35,72). ACS is the second most common cause of 




SCD(2,49,72); it is also a leading cause of death for patients with SCD(2). ACS 
cases are often proceeded by an acute vasoocclusive event(2). The underlying 
cause of ACS remains unknown, but factors that may play a role in this process 
include infection, fat or bone marrow embolism, hypoventilation/atelectasis, and 
vaso-occlusion of the pulmonary vasculature(35). Additionally, hypercoagulable 
state is known to be present in SCD(51), and pulmonary thromboses may also 
occur in the setting of ACS (51). 
Acute splenic sequestration: Acute splenic sequestration crisis is 
defined as an acute splenic enlargement with greater than a 2 g/dl decrease in 
hemoglobin concentration from baseline(35,73). Splenic sequestration crises are 
reported to occur in 30% of young children with SCD(2). It is a severe 
complication that leads to an acute decline in hemoglobin level and sequestration 
of a large proportion of blood volume in the spleen producing hypovolemic 
shock(35). Splenic sequestration crises can occur for the first time in young 
children with SCD with a median age of 1.4 years(35).  
Acute renal injury: Acute renal injury is defined by an acute decline in 
renal function(35). Acute renal injury occurs in 4-10% of hospitalized patients with 
SCD(74). It is more frequent in patients with ACS (13.6%)(35,74) than in patients 
with uncomplicated vasoocclusive crises (2.3%)(74). Acute renal injury can be pre-
disposed by volume depletion, rhabdomyolysis, infection, and nephrotoxic 





Acute hepatic complications: There are several acute hepatic 
complications observed in SCD patients. Patients with SCD may experience 
acute hepatic sequestration crises; however, this is less common than splenic 
sequestration crises(75) but can also lead to acute hypovolemic shock and 
mortality if not appropriately cared for(35,75). An acute sickle hepatic crisis, 
observed in 10% of SCD patients presenting with VOC (75) is considered due to 
ischemia related to sinusoidal obstruction(75). Acute intrahepatic cholestasis, 
although rare, is the most severe acute hepatic complication(75). It is thought to 
be an unusually severe form of a sickle hepatic crisis(76).  
Acute neurologic complications: Strokes are devastating complications 
of SCD(35). In the absence of transcranial Doppler screening (which identifies a 
high risk population that are prophylactically treated to reduce stroke risk), 
arterial ischemic stroke occurs in about 5-10% of children with SCD(35). By the 
age of 20 years, the cumulative risk for overt stroke in SCD patients is 11%(35) 
and by age 30 and 45 years, it is 15% and 24%, respectively(35). Hemorrhagic 
stroke is more frequently seen between the ages 20-29 years and very rarely 
seen outside that range(77). Silent cerebral infarcts occur in approximately 25% of 
children with SCD before the age of 6 years(35,77). Silent infracts are associated 
with significantly poor cognitive and academic functional performance(35), which 
can affect psychological well-being and the ability of adults with SCD to attain 
employment(35). Recurrent strokes happen in 50-75% of untreated SCD 




another neurological complication in SCD(77,78). In individuals with SCD, PRES is 
less common than stroke(78), but it can present with acute neurological changes 
that initially mimic stroke(78). PRES is characterized by reversible radiographic 
signs of posterior leukoencephalopathy(78) in the presence of confusion, 
headache, and seizures with or without visual disturbances(77,78). The reversible 
radiographic signs are of distinctive importance because stroke shows 
irreversible radiographic signs(78). The etiology of PRES remains unknown(77,78), 
but it is thought that endothelial and cerebral autoregulation dysfunction and 
vasoconstriction leading to ischemia and blood brain barrier disruption is the 
cause(77).  
Priapism: Priapism is defined as an unwanted or sustained painful 
erection in the absence of sexual activity(35,49). It is a common and severe 
complication, and prolonged episodes of priapism can lead to irreversible 
changes, including tissue necrosis, fibrosis, and erectile dysfunction(35,49). 
Priapism is considered a medical emergency and requires immediate 
intervention(35). Other acute complications of SCD are summarized in Table 1.2. 
 
1.2.3.2 Chronic complications 
Chronic pain: Chronic pain is experienced by a large proportion of 
patients with SCD(35,79). The mechanism of chronic pain differs from that of acute 
pain, which arises from vasoocclusive episodes(35). The etiology of chronic pain 




secondary to avascular necrosis of various joints(35). Approximately 17-30% of 
adults with SCD experience daily pain(35) while 40% of children and adolescents 
aged 8-18 years have chronic pain(35).  
Avascular necrosis (AVN): Also known as osteonecrosis(35), it is one of 
the most devastating musculoskeletal complications for SCD patients(35,49). AVN 
affects 50% of SCD patients by the age of 35(35). The exact pathophysiology is 
not well determined, but it is thought that repeated vaso-occlusion leads to tissue 
hypoxia, reperfusion injury and inflammation, and ultimately bone necrosis(35). 
The most common sites are the femoral(35,49,79) and humeral heads(35,79), leading 
to damage to the articular surface of the hip and shoulder joints(35,49). Patients 
may be asymptomatic during the early stages of AVN, which might delay 
diagnosis(35). Movement limitation at the affected site with pain at rest is the 
common symptoms of AVN (35). If left untreated, AVN can lead to loss of function 
in the affected joint(35,49). 
Chronic hemolytic anemia: Patients with SCD experience chronic 
hemolysis, leading to anemia(51). However, this chronic anemia can have periods 
of acute worsening (due to hyperhemolytic , aplastic ,or splenic sequestration 
crises)(2,35). Sickled RBCs undergo hemolysis, with a life span of approximately 
10–20 days, leading to chronic hemolytic anemia(2,35). Patients with SCD have a 
baseline level of hemolysis. Individuals with anemia can experience shortness of 
breath, fatigue, and in children, anemia can delay growth(42). Compensatory 




typically be sufficient to prevent major symptoms of anemia, however, such 
compensation and deleterious effects from hemolysis over time leads to cardiac 
complications(51). 
Cardiac complications: Cardiac complications, namely left ventricular 
dysfunction and right ventricular dysfunction(80), are a common cause of morbidity 
and mortality in SCD(80). Left ventricular dysfunction includes : 1) Left ventricular 
dilation, in part due to chronic anemia, and hypoxemia, leads to increased 
cardiac output with a minimal increase in heart rate(80). 2) Increased left 
ventricular mass and diastolic dysfunction; over time, progressive left ventricular 
dilation leads to increased wall stress and increased left ventricular mass(80). 
Doppler studies have shown that diastolic dysfunction is common in children and 
adults with SCD(80) which is an independent risk factor for mortality(80). 3) Left 
ventricular systolic dysfunction, defined by depressed left ventricular ejection 
fraction, has been observed in some studies in patients with SCD(80,81). The 
reduction of left ventricular ejection fraction is associated with a high mortality 
rate(51). 
Right ventricular dilation has been observed in steady state and without 
pulmonary hypertension(80). Elevated tricuspid regurgitant velocity (TRV) is a 
common finding in patients with SCD, and it has been associated with pulmonary 
hypertension and right ventricular dysfunction(80). 
 Iron overload, known as hemochromatosis, from frequent blood 




of patients(51). Myocardial iron overload is directly related to systolic and diastolic 
dysfunction and arrhythmic complications observed in SCD patients(51).  
Pulmonary complications: Hyper-reactive airway disease or asthma is 
very common in patients with SCD(72). Approximately 77% of children and 
adolescents with SCD have hyper-reactive airways(50). The mechanism of 
asthma in SCD is complex and not very well understood (72). Frequent ACS may 
contribute to lung inflammation and increase bronchial hyper-reactivity(72). 
Pulmonary hypertension is another chronic pulmonary complication and is fairly 
common in SCD (observed in 6-10.4% of adults with SCD)(50); it is defined by 
mean pulmonary arterial pressure > 20 mm Hg(82). It is a severe complication and 
an independent risk factor for mortality(72). Pulmonary hypertension is associated 
with more severe anemia , increased serum lactate dehydrogenase and bilirubin 
(indicating high level of hemolysis)(83,84).  
Chronic hepatobiliary complications: Frequent blood transfusions can 
put patients with SCD at risk for chronic viral hepatitis, such as hepatitis B, 
although this is rare due to 1) The improved screening of donor blood and 2) The 
use of hepatitis B vaccine(85). Hepatitis C is also rare due to the improvement of 
donor blood screening; however, the risk is there and directly correlated with the 
frequency of blood transfusions received(85). Iron overload (hemochromatosis) is 
another complication that is directly correlated with the frequency of blood 




to liver cirrhosis(75,85). In an autopsy series, 16–29% of patients with SCD showed 
liver cirrhosis(85).  
Cholelithiasis (pigmented gallstones) is common in patients with SCD, and 
it is directly related to the rate of hemolysis(79). Gallstones may occur in children 
(3–4 years old) and are eventually found in approximately 70% of patients(85). 
Sickle cell nephropathy: Renal disease is very common in SCD(35). The 
glomerular filtration rate (GFR) starts to decline after the age of 16 years(35). 
Proteinuria occurs in 27% of SCD patient in the first 3 decades of life(35). Renal 
damage is a sign of poor prognosis in SCD patient and accounts for 5-18% of 
mortality(35). Renal damage in SCD is thought to be related to vaso-occlusive as 
well as to hemolysis related endothelial dysfunction vasculopathy(86) (vaso-
occlusive and hemolysis sub-phenotype will be discussed in section 1.2.5.6). For 
the vaso-occlusive type, the renal medulla is main site of insult as it is supplied 
by vasa recta capillaries(86). The hypoxic, acidic, and hypertonic environment in 
the vasa recta capillaries promotes vaso-occlusion, which causes renal 
medullary ischemia and infarction, leading to hematuria, papillary necrosis and 
tubular acidosis(35,86). Vaso-occlusion in the vasa recta capillaries may also lead 
to the loss of deep juxtamedullary nephrons and reduced countercurrent 
exchange in the inner medulla, leading to impaired free water reabsorption and 
urinary concentrating ability (hyposthenuria), a common finding that may 
contribute to volume depletion, nocturia, and polyuria(35,86).The hemolysis 




hyperfiltration and glomerulopathy(86). Free heme from hemolysis stimulates a 
pro-inflammatory effect that causes an insult to the renal vascularity by inducing 
monocyte chemoattractant protein-1, a vasculopathic chemokine(86). Other 






























 Acute Chronic 
Pain VOC, ACS 







Aplastic crisis, splenic 
sequestration crisis, 
hyperhemolytic crisis 
Compensated hemolytic anemia, 
chronic hypersplenism 
CNS 
Ischemic stroke, hemorrhagic 
stroke, seizures, TIA 
Silent cerebral infarctions, cognitive 
delay, behavioral issues 
Pulmonary 




disordered breathing, chronic 
restrictive lung disease 
Renal 
Renal infarction, medication 
(NSAIDs) toxicity, hematuria, 
acute renal failure, acute 
nephrotic syndrome 
Hypertension, chronic renal failure, 
renal concentrating defect, 
nephrogenic diabetes insipidus, 
renal medullary carcinoma 
Skeletal Dactylitis, AVN Osteoporosis, osteomyelitis 
Cardiac 
Myocardial infarction (rare), 
arrhythmia, sudden death, 
autonomic dysfunction 
Diastolic dysfunction, heart failure 
Hepatobiliary 
Hepatic sequestration crisis, 
cholecystitis, liver injury, 
acute intrahepatic cholestasis 
Pigment gallstones 
Ocular 
Retinal artery occlusion, 
retinal detachment 
Proliferative retinopathy, blindness 
Obstetric 
Fetal and maternal 
complications 
 
Genitourinary Priapism Erectile dysfunction 
Endocrine  Delayed puberty, reduced growth 
Vascular  Leg ulcers 
Other Venous thromboembolism Functional asplenia 
Table 1.2. Overview of acute and chronic complications of sickle cell 
disease  
 
CNS = Central nervous system, VOC = Vaso-occlusive crises, ACS = Acute 
chest syndrome, CNS = Central nervous system, TIA = transient ischemic 







1.2.3.3 End organ damage 
 With improved care, more than 90% of children with SCD reach adulthood 
in high-income countries and the aging population with SCD leads to the 
emerging of SCD-associated end-organ damage(88,89). Complications such as 
stroke, chronic renal disease, and cardiopulmonary disease contribute 
significantly to the morbidity and early mortality in adults with SCD(88). In one 
study which included 150 SCD patients, end-organ damage occurred in 1,2 or 3 
organs in 35.5%, 19.3% and 4.7% of patients, respectively(88). However, 40.7% 
of individuals had no evidence of end-organ damage. The study also reported 
that the number of impaired organs was associated with the mortality rate in 
these patients and was a significant predictor of survival(88). The pathophysiology 
of end‐organ damage in SCD is complex and involves numerous overlapping 
mechanisms. Erythrocyte decay‐associated molecular patterns is a term used to 
include(88): 1) The disruption of the arginine‐nitric oxide pathway 2) Heme‐
induced oxidative damage 3) Activation of toll‐like receptor 4 and inflammasome 
pathways(88). Despite the abundance of clinical and basic research on SCD 
complications, a cohesive mechanism that explains multiple organ vasculopathy 
remains elusive, and management of chronic organ complications due to 





1.2.4 Sickle cell disease variants 
SCD is a group of hemoglobinopathies inherited in an autosomal 
recessive manner(35,90). Patients with homozygous HbSS have the most severe 
disease manifestation(35,37,40). The co-inheritance of sickle cell mutation with other 
mutations in the β-globin gene leads to disorders such as Hemoglobin SC 
disease (HbSC) disease and sickle cell-beta thalassemia(35).  
HbSC disease is characterized by the presence of hemoglobin C (HbC) 
and HbS and the absence of HbA(90). HbC is caused by a mutation in the same 
amino acid position as in the HbS mutation, but it substitutes glutamic acid with 
lysine(91). HbC does not polymerize but it contributes indirectly to deoxy-HbS 
polymerization(35). The effects of HbC are observed owing to enhanced and 
persistent K+ and Cl- co-transport leading to K+ loss(35,91). Dehydration of RBCs 
caused by the loss of K+ leads to an increase in the intra-erythrocytic 
concentration of HbS, which aids its polymerization(2,35). In the US, HbSC occurs 
in one-third of patients with SCD(35,90). Patients with HbSC disease have similar 
complication risks as those with HbSS but these generally occur at a lower 
frequency(90). Uniquely, HbSC patients have a higher risk of peripheral 
retinopathy and systemic and cerebral fat embolism(35,90). 
Sickle cell-beta thalassemia (HbS-β thalassemia) is divided into HbS-β0 
thalassemia and HbS-β+ thalassemia based on the complete absence of β-globin 
(β0) or the presence of a markedly reduced amount of β-globin (β+), 




quantity of functional HbA being produced(35,37). Patients with HbS-β0 
thalassemia have a similar clinical severity as SCA (HbSS)(35). In contrast to 
HbSS patients, patients with HbS-β0 thalassemia do not experience rapid splenic 
infarction, but they continue to have splenomegaly into adulthood, which places 
them at risk for acute splenic sequestration(90). Patients with HbS-β+ thalassemia 
usually have less severe clinical course compared with those with HbS-β0 
thalassemia and HbSS(35). Nevertheless, patients with HbS-β+ thalassemia with 
β+ mutation IVS1-5(G->C) have severe clinical manifestations similar to patients 
with HbSS(90). This is attributed to the low HbA levels (less than 7%) in patients 
with the IVS1-5(G->C) mutation(90).  
Sickle cell-alpha thalassemia is another SCD variant(35,92). Alpha 
thalassemia (α-thalassemia) is characterized by reduced production of the α-
globin chain(35,92). The presence of α-thalassemia in SCD has a beneficial effect 
on the pathophysiology of SCD(35) because reduced production of α-globin leads 
to a deficiency in the amount of hemoglobin per cell(35). In sickle cell-α-
thalassemia, the number of irreversibly sickled RBCs and dense RBCs is 
reduced, and RBC deformability is higher(35,93). The HbS concentration per cell is 
reduced, leading to lower deoxy-HbS polymerization and hemolysis, which in turn 
improves the anemia(35,93). Nevertheless, the other clinical symptoms in sickle 
cell-α-thalassemia are variable(90). It has been reported that certain complications 
like VOC, ACS, and osteonecrosis are higher in patients with sickle cell-α-




stroke, leg ulcers, glomerulopathy, and priapism, are lower in sickle cell- α-
thalassemia(84,94,96). Additionally, it was reported that patients with sickle cell-α-
thalassemia showed a reduced response to HU treatment(97). 
Sickle-hereditary persistence of fetal hemoglobin (HbS-HPFH) is yet 
another variant characterized by high HbF levels(98). HPFH is divided into two 
main groups; deletional HPFH that is caused by variable length deletion in the β-
globin gene cluster leading to a decrease or an absence of β-globin synthesis 
with a variable compensatory increase in γ-globin synthesis(98) which leads to 
pancellular distribution of HbF among erythrocyte(98). The co-inheritance of this 
HPFH (deletional) with SCA, ameliorates the disease as patients show no 
symptoms or any complications from SCA(98). The second group is non-deletional 
HPFH, which typically leads to increased HbF but with heterocellular distribution 












1.2.5 Pathophysiology of sickle cell disease 
1.2.5.1 Deoxy-HbS polymerization  
Hemoglobin A (HbA) remains in solution during the shift between 
oxygenation and deoxygenation(40). In contrast, deoxygenated HbS polymerizes 
into rigid strands(40,99). The polymers are a complex helical structure of fourteen 
fiber strands arranged in seven pairs of double-stranded fibers(100). Each fiber 
strand is composed of deoxygenated HbS (deoxy-HbS) arranged in an axial 
array(101). As the polymerization of deoxy-HbS inside the RBCs occurs, the RBCs 
take a sickle shape instead of being biconcave(102). Initially, this process is 
reversible, but after several cycles of deoxygenation and reoxygenation, the 
RBCs become permanently sickled(102). Consequently, RBCs become rigid and 
susceptible to hemolysis(2,103), and this reduces their life span to 10-20 days(49) 
(normal RBCs life span is 120 days(49)). The density of these cells increases 
owing to deoxy-HbS polymerization. In turn, blood flow and vascular endothelial 
integrity are affected(2,24,36). Owing to the mechanical strain from the sickling of 
the RBC membrane, a piezo-type mechanosensitive ion channel (PIEZO1) gets 
activated, resulting in an influx of Ca2+(2,91,104), and efflux of Mg2+(91). The 
substantially increased concentration of Ca2+ results in the activation of the K+ 
channel (Gardos channel(2,91)) that leads to K+ loss at a high rate(2,91). 
Additionally, the KCl cotransporter became active, mediates coupled efflux of K+ 
and Cl- leading to further loss of K+(2,91). This intracellular electrolyte imbalance 




of HbS in the RBCs, promoting further sickling(2,91) (Figure 1.3). Notably, the 
Ca2+ concentration depends on ATPase; however, the role of Ca2+ in membrane 
rigidity is unclear(2). 
 
Figure 1.3. HbS polymerization and electrolyte imbalance in a red blood 
cell.  
Long polymers of HbS align to form fibers, which then align to form parallel rods. 
HbS polymerization depends on various factors, including HbS concentration, 
presence of different Hb molecules, partial pressure of oxygen (pO2), 
temperature, pH, and concentration of 2,3-diphosphoglycerate (2,3-DPG). 
Double nucleation is the fundamental concept underlying HbS polymerization. 
There is a latency period before any polymers can be detected; during this delay, 
deoxy-HbS molecules form a small nucleus, which is followed by rapid polymer 
progression. The presence of free cytoplasmic heme amplifies the attraction of 
the HbS molecules and the speed of nucleation. Dehydration of cells is caused 




intermediate-conductance Ca+2-activated K channel protein 4 (Gardos channel) 
and K-Cl cotransporter 1 (KCC1). Plasma adenosine can also reprogram the 
metabolism of erythrocytes, altering sphingosine-1-phosphate (S1P), leading to 
decrease HbS affinity to oxygen. ADORA2B = adenosine receptor A2b, AE1 = 
band 3 anion transport protein, HbA = hemoglobin A, HbF = fetal hemoglobin. 
(Adapted and redrawn from Kato et al., 2018(2)).  
 
1.2.5.2 Role of HbF in hindering deoxy-HbS polymerization 
 The symptoms of SCD appear several months after birth as HbF level 
declines and is replaced by HbS(105,106). HbF reduces the concentration of HbS; 
additionally, HbF cannot enter into the deoxy-HbS polymerization(105,106). 
Additionally, mixed hybrid tetramers (α2γβS) fail to enter in the HbS 
polymerization(39,105) in contrast to the hybrid tetramer (α2βSβA) that has 50% 
probability to enter the polymerization(39,106). This is because of the β 87 
threonine, which is of critical importance in the formation of the β6 valine 
hydrophobic acceptor pockets(39,107), is replaced by glutamine in the γ-globin(107); 
consequently, the hybrid tetramer (α2γβS) hinders the HbS polymerization(107) 
(Figure1.4). Thus, the unique property of HbF inhibits the tendency of deoxy-
HbS polymerization and preventing cellular damage(106). Nevertheless, to 
completely thwart the dexoy-HbS polymerization, HbF amount should reach a 






Figure 1.4. Hybrid HbF/S render the HbS polymerization 
This figure illustrates that the hybrid HbF/S (α2γβS) has an anti-sickling effect in 
contrast to the HbA/S (α2βSβA) hybrid hemoglobin. This is due to the 
replacement of the amino acid at 87 position threonine in β- globin by glutamine 
in the γ-globin, which disturbs the hydrophobic acceptor pocket and makes it 
weaker to bind β6 valine. (Adopted and redrawn from Lettre and Bauer, 2016(3)). 
 
1.2.5.3 Vaso-occlusion in sickle cell disease 
In healthy individuals, RBCs with HbA glide smoothly through small blood 
vessels. In individuals with SCD, deoxy-HbS undergo polymerization, making 
RBCs stiff and preventing them from gliding smoothly through blood vessels(2). 
This leads to vaso-occlusion, which may lead to tissue ischemia and infarction(2). 
Vaso-occlusion is a complex complication, and it is characterized by abnormal 
interaction between RBCs, leukocytes, and platelets with the vascular 
endothelium (Figure 1.5)(2). The membrane of the sickled RBCs is damaged, and 
it promotes the expression of adhesion molecules such as integrin-associated 




expressed(36). In addition, owing to chronic anemia, stress erythropoiesis leads to 
the release of immature reticulocytes(49). These reticulocytes are rich in adhesion 
molecules such as very late antigen-4 (VLA-4) (also known as integrin α4β1)(2,36) 
and CD36 (also known as platelet glycoprotein 4)(2,36). Endothelial cells are 
activated by 1) Direct contact with sickled RBCs, 2) Free Hb, and 3) Reactive 
oxygen species (ROS), which leads to increased expression of endothelial 
adhesion molecules such as vascular cell adhesion protein 1 (VCAM-1), E-
selectin, and P-selectin(2,36). The adhesion of the sickle cell to the vascular 
endothelia may be summarized in three steps(109) 1) Initial contact, mediated by 
erythrocyte P-selectin ligand, and sialylated carbohydrate ligand binding to 
endothelial P-selectin and E-selectin, respectively(109) 2) Rolling adhesion 
facilitated by the same adhesion molecules(109) 3) Firm adhesion, which involves 
several adhesion molecules (such as erythrocyte CD36 binding to endothelial 
αVβ3, and VLA-4 directly binding VCAM-1)(109).  
Moreover, activated endothelial cells produce inflammatory mediators 
such as Interleukin-6 (IL-6) and IL-1β; as a result, neutrophils, monocytes, and 
platelets migrate to the site of inflammation(2). Neutrophils get activated and 
demonstrate increased expression of αMβ2 integrin, which promotes their 
adhesion to RBCs(110); furthermore, selectins produced by the endothelial cells 
play an important role in neutrophil adhesion(2,36). The role of neutrophils in VOC 
in SCD has been observed in the rare co-inheritance of SCD with severe 




complications compared to their siblings with SCD(110,111). However, once the 
patient received granulocyte colony-stimulating factor (G-CSF) to treat 
neutropenia, the course of SCD dramatically worsened(110,111).  
Platelets also play an essential role in the pathophysiology of the vaso-
occlusion(2). Platelets are activated in SCA, and they express high levels of P-
selectin and activated αIIbβ3 integrin, which contributes to the adhesion of 
neutrophils and the sickled RBCs forming aggregates(2,110). 
In conclusion, vaso-occlusion is a complex process, with interaction 
between adhesion molecules and the sickled RBCs, endothelial cells, leukocytes, 










Figure 1.5. Mechanism of vaso-occlusion.  
An illustration shows molecular and cellular interactions that influence the 
development of vaso-occlusion in SCD. Endothelial cells get activated by sickled 
RBCs, hemoglobin, or ROS, and once they are activated, endothelial adhesion 
molecules such as vascular cell adhesion protein 1 (VCAM-1), E-selectin, and P-
selectin are up-regulated leading to adhesion of RBCs and neutrophils(110). 
Platelets also play a role in the vaso-occlusion pathology as they create 
aggregates of neutrophils and RBCs (primarily reticulocytes)(2). Serine/threonine 
kinase (AKT2) in neutrophils is essential for their crawling and platelet-neutrophil 
interaction on the activated endothelial cells during VOC, inhibition of AKT2 
diminish this interaction and improve blood flow(110). (Adopted and redrawn from 




1.2.5.4 Oxidative stress 
Oxidative stress, another factor responsible for the pathophysiology of 
SCD, has different sources(113). RBCs in SCD are rich in reactive oxygen species 
(ROS) owing to deoxy-HbS polymerization and de-polymerization, a process that 
increases ROS generation(113). Auto-oxidation of hemoglobin is a physiological 
phenomenon that can occur and lead to the production of methemoglobin and 
superoxide (O2•-)(114). HbS auto-oxidation is 1.7-fold faster than HbA(113,114). 
Various studies have reported that generation of O2•-, hydrogen peroxide (H2O2), 
hydroxyl radical (HO•), and oxidation of lipids in sickle erythrocytes is two-fold 
faster than that in HbA-containing erythrocytes(113). The RBC plasma membrane 
is the target for those free radicals leading to increased permeability and 
inactivity of membrane receptors and enzymes(114). Erythrocytes have protective 
enzymes that neutralize these free radicals, such as superoxide dismutase, 
catalase, and glutathione peroxidase, but those enzymes have diminished 
activity in sickled RBCs(114). Therefore, in sickled RBCs, there is 1) Increase 
production of ROS and 2) Ineffective ROS removal(113,114). In addition, owing to 
chronic hemolysis, patients with SCD show substantially high plasma levels of 
cell-free hemoglobin (Hb)(24,103,113). Haptoglobin and hemopexin, which bind cell-
free Hb, becomes depleted in SCD as a result of persistent increased 
hemolysis(103). Cell-free Hb(Fe2+) reacts with nitric oxide (NO), leading to its 
depletion and the formation of nitrate (NO3-) and methemoglobin (Fe3+)(36). 




reaction and forms hydroxyl free radicals (HO·) and methemoglobin(36). Another 
source of ROS is the polymorphonuclear leukocytes (PMNs), such as 
neutrophils; Neutrophils get activated by free plasma Hb, which promotes 
oxidative burst leading to the rapid release of ROS, which causes tissue 
damage(36). An additional source of oxidative stress in SCD is ischemia-
reperfusion injury(36,115). Restoration of oxygen-rich blood flow after ischemia is 
challenging, and it frequently results in tissue damage(115) described as 
reperfusion injury(36). In conclusion, the sources of oxidative stress are 1) The 
sickled RBCs 2) Hemolysis and free plasma Hb 3) PMN activation, and their 
oxidative burst 4)Ischemia-reperfusion injury related to vasoocclusion(2,36,103,115).  
 
1.2.5.5 Nitric oxide depletion 
Nitric oxide (NO) is another important factor that contributes to SCD 
pathophysiology(2,36). NO is a crucial endothelium-derived vasodilator produced 
from L-arginine (a precursor for NO synthesis) by a group of enzymes called 
nitric oxide synthases (NOS)(94,116). There are three types of NOS, neural NO 
synthase encoded by NOS1, macrophage-inducible NOS encoded by NOS2, and 
endothelial NOS (eNOS) encoded by NOS3 (83,116). NO can also be produced by 
the reduction of one of its congeners(116). Endothelial NO can 1) Inhibit platelet 
activation, thrombosis, and RBC adhesion to endothelial cells(116). 2) Inhibits 
monocytes and leukocyte adhesion to the endothelial cells (117). 3) NO is an 




smooth muscle cells and binds to soluble guanylyl cyclase, which produces a 
secondary messenger cyclic guanosine monophosphate (cGMP) leading to a 
cascade that relaxes the blood vessel wall and increases blood flow(83,94,116,117). 
4) Inhibit LDL oxidation(117). Reduced NO bioavailability is involved in the 
pathophysiology of pulmonary hypertension in SCD(81). The bioavailability of NO 
in SCD may be reduced by the following factors: 1) Sustained free Hb owing to 
chronic anemia that will react with NO via NO deoxygenation 
reaction(83,94,116)(Figure 1.6). 2) Elevated levels of plasma arginase owing to RBC 
hemolysis: It leads to a reduction of L-arginine and reduces NO 
production(81,83,116) (Figure 1.6). Additionally, through uncoupled endothelial NO 
synthase (eNOS), ROS are generated, leading to endothelial dysfunction(36). 3) 
Increased NO consumption by ROS(83,116). 4) High levels of asymmetric 
dimethylarginine (ADMA), an endogenous NOS inhibitor(81). ADMA is generated 
by proteolysis of methylated arginine containing proteins(118). ADMA level is high 
in SCD patients, and it is associated with markers for hemolysis (such as lactate 
dehydrogenase, low Hb concentrations and high reticulocyte counts), markers for 
endothelial activation(118) (such as soluble vascular cell adhesion molecule-1), 
pulmonary hypertension, and early death(81). It is not clear why ADMA is high in 
SCD, but it has been speculated that it can be due to 1) Increase production by 
the proteolysis of proteins released during RBC hemolysis(118). 2) Hemolysis 




broke down ADMA)(118). 3) Increase in arginine methyltransferase activity from 
endothelial shear stress(118).  
 
Figure 1.6. An overview of hemolysis-endothelial dysfunction. 
During hemolysis, red blood cells release free plasma hemoglobin and arginase, 
which interact with nitric oxide (NO), a powerful vasodilator, leading to its 
depletion. 1) L-Arginine is the precursor for NO production by the endothelia via 
an enzyme NO synthase (NOS3). Arginase degrades L-arginine, leading to 
reduced production of NO. 2) Free plasma hemoglobin interacts with NO present 
in the plasma, producing methemoglobin and nitrate, which lead to depletion of 
NO. These events can occur during steady state in patients with SCD and can 
underlie clinical complications including pulmonary hypertension. 3) During VOC, 
NO binds to the free radicals produced after re-perfusion, preventing them from 
causing damage. However, this eventually also leads to NO depletion, which 




vascular remodeling seen in SCD. (Adapted and redrawn from Habara and 
Steinberg, 2016(1)).  
 
Environmental factors play a role in the clinical variability of SCD(119). For 
example, exposure to cold and windy weather has been associated with VOC in 
SCD patients(119). Although the causality is not established, it is thought that upon 
exposure to cold, peripheral vasoconstriction occurs, and the velocity of blood 
flow is reduced, leading to greater deoxygenation of blood, which ultimately leads 
to sickling of RBCs and VOC(119). Similarly, wind is associated with VOC; various 
studies reported that there were significantly higher VOC hospitalizations on days 
with higher wind speeds than on days with lower wind speeds(119,120).  
Based on the available information, it appears that deoxy-HbS 
polymerization emerges as the primary event in the pathophysiology of SCD. The 
polymerization of deoxy-HbS can be most appropriately explained through a 
double-nucleation mechanism(121). However, polymerization alone does not 
account for the entire pathophysiology of SCD(122). Other events downstream of 
deoxy-HbS polymerization, such as changes in RBC membrane structure, 
electrolyte imbalance, thrombosis, increased adhesion of circulating blood cells 
to the vascular endothelium and reduced NO bioavailability have all been 





1.2.5.6 Vaso-occlusion and hemolysis sub-phenotype 
The clinical variability of SCD and the complex nature of its 
pathophysiology indicate that other genes may modify the course of this 
disease(1,2). For instance, increased HbF expression can ameliorate the disease 
severity(4,115). Also, the co-inheritance of α-thalassemia improves some of the 
complications (discussed earlier section 1.2.4)(1,2,35). Vaso-occlusion and 
hemolysis are two sub-phenotypes in SCD(1,2). However, these phenotypes are 
not mutually exclusive and they exist in wide variability (1,2).  
The vaso-occlusive sub-phenotype is characterized by a higher 
hemoglobin concentration and lower serum lactate dehydrogenase (indicative of 
low levels of hemolysis)(1,2). The co-inheritance of α-thalassemia lead to reduce 
hemolysis and increase hematocrit(2,84). The vaso-occlusive sub-phenotype is 
characterized by an increase in VOC, ACS and osteonecrosis(1,2) and less leg 
ulcer, pulmonary hypertension, priapism and stroke(1,2,84). High level of HbF is 
protective for this sub-phenotype(1,84). 
The other sub-phenotype is the hemolysis-endothelial dysfunction sub-
phenotype, also known as hemolysis and vasculopathy sub-phenotype(2,84). It is 
characterized by lower hemoglobin concentrations, elevated reticulocyte counts,, 
serum lactate dehydrogenase and bilirubin levels (indicative of increased 
hemolysis)(1,2,84). Individuals with this sub-phenotypes are at risk of strokes, 
pulmonary hypertension, leg ulcers, biliary tract and renal complications(1,2,83). In 




to be protective in the hemolysis-vasculopathy sub-phenotype(1,83,84). Insufficient 
levels of HbF in some RBCs, leading to continuous intravascular hemolysis and 
endothelial damage over time may have some role in this process but this 
remains unclear(83). 
 
1.2.6 Genetic regulation of HbF  
HbF concentration is genetically modulated; five common β-globin gene 
cluster haplotypes are associated with HbF(4,123) (Table 1.3). Nevertheless, the 
percentage of HbF in patients homozygous for the BEN and CAR haplotypes 
from Western Saudi Arabia is twice the level in African American patients(4). This 
finding indicates that other genetic elements contribute to HbF expression.  
 










Haplotype HbF % 
AI/AI 18.03 ± 5.4 
SEN/SEN 9.24 ± 5.3 
CAM/CAM (CSSCD) 7* 
BEN/BEN (CSSCD) 6.7 ± 5.6 
BEN/BEN (SW) 11.22 ± 5.32 
CAR/CAR (CSSCD) 5.52 ± 3.7 
CAR/CAR (SW) 9.35 ± 5.7 
Table 1.3. Different SCA haplotypes with their HbF percentages. 
 
AI = Arab-Indian, SEN = Senegal, CAM = Cameroon, BEN = Benin,  
CAR = Central African Republic. SW = Saudi West population, CSSCD = African 





Other single nucleotide polymorphisms (SNPs) located in the 
hypersensitive site (HS) of the β-globin cluster have been explored. The SNPs in 
the ZBTB7A-binding HS region distinguish the Arab-Indian (AI) haplotype from 
the African-origin HBB haplotypes(4) (Figure 1.7). ZBTB7A is a zinc finger protein 
that was found to have a role in hemoglobin switching(124).   
Homozygosity for the minor alleles (T/A/T) in rs16912979, rs7119428, and 
rs7482114, respectively, are restricted to the AI haplotype(4). rs16912979 and 
rs7119428 are hypothesized to form a functional site for ZBTB7A binding(4,125) or 
to be in linkage disequilibrium with the functional site(4,125). Figure 1.7 presents a 
more detailed explanation regarding these SNPs and their effects on the 







Figure 1.7. Cis-acting elements associated with HbF levels in Arab-Indian 
(AI), Senegal, and Benin haplotypes.  
The AI haplotype (top panel), characterized by high HbF, represented by the 
alternative T allele of rs16912979 and the A allele of rs7119428, is hypothesized 
to interact, via the LIM domain binding 1 (Ldb1) complex, with the T allele of 
rs7482144 5ʹ to HBG2, thus promoting its expression. This interaction results in 
increased expression of HBG2 and, therefore, high levels of HbF. In the Benin 
haplotype (bottom panel), which is characterized by low HbF, the wild-type 
alleles of the three SNPs, C, C, and C respectively, promote the interaction of the 




The Senegal haplotype (center panel) contains the wild-type C alleles of 
rs16912979 and rs7119428, but the alternative allele T of rs7482144, which is 
characteristic of this haplotype, promotes interactions between the locus control 
region (LCR) and HBG2 promoter, leading to moderate HbF levels. It should be 
noted that functional data are necessary to prove these hypothesized 
interactions. (Obtained from Habara et al., 2017(4)). 
 
Trans-acting elements have also been explored; among African SCA 
haplotypes, polymorphisms in BCL11A and MYB account for approximately 10–
50% of HbF variance(4,126). In the AI haplotype, MYB has a minimal role, perhaps 
owing to the rarity of the functional 3 bp deletion in one of the enhancers(4). 
Likewise, the BCL11A polymorphism showed a minor effect on HbF levels in the 
AI haplotype(4).  
ANTXR1, an anthrax toxin receptor, was found to be associated with HbF 
levels in the AI haplotype(4,127). The ANTXR1 polymorphism accounts for 10% of 
HbF variability, independent of BCL11A(4,127). Nevertheless, a functional study is 
required to determine the role of ANTXR1 in HBG regulation.  
There has been substantial progress in research on the role of other 
erythroid-related genes pertinent to the repression or activation of HbF 
expression. Figure 1.8 shows the role of transcription factors in hemoglobin 
regulation. Table 1.4 summarizes some of the genes that play a role in HBG to 




variability in HbF levels, but their binding motif loci may have SNPs that 
contribute to the HbF level variation among the different SCA haplotypes(4).  
 
Figure 1.8. Hemoglobin transcription factors effect on the β-globin gene 
cluster 
The Ldb1 complex facilitates the lopping between the locus control region (LCR) 
and gene promoters. The red and blue stars indicate the binding domain for 
BCL11A and ZBTB7A (LRF) transcription factors, respectively. The presence of 
SNPs in these binding motifs could modulate the binding of BCL11A and LRF 
that are associated with two nucleosome remodeling and deacetylase (NuRD) 
complexes. It should be noted that BCL11A prefers binding to the distal γ-globin 




expression indirectly by stimulating KLF1. KLF1 stimulate BCL11A(4,129) and 
LRF(130) that ultimately silences HBG expression. Silent mating type information 
regulation 2 homolog 1 (SIRT1) is a direct and indirect stimulator on the HBG 
expression(131). PGC-1α is thought to work as a stimulator on HBG expression, 
but whether its effects are direct or indirect is still to be determined. Additionally, 
it is thought that lysine-specific demethylase 1A (LSD1) inhibits PGC-1α(10), 
indicating a complex mechanism involving the PGC-1α regulation on HBG 
expression. (not drawn to scale; adopted and modified from Habara et al., 
2017(4). SIRT1 effect on HBG regulation was obtained from Dai et al., 2017(131). 
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The master controller of 
HBG to HBB switching 
Pomalidomide 








Causes active chromatin 
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HDAC inhibition.  
Entinostat inhibits HDAC1, 2, and 
3.  
ACY-957 is 100-fold more 





Affects KLF1 expression   (142) 
ANTXR1 Inhibition 
Effect on HBG only 
hypothesized 
  (127) 
Table 1.4. Gene/transcripts with roles in HBG to HBB switching.  















Involved in maintaining 





Decitabine (DNMT1 Inhibitor) is 
rapidly metabolized by cytidine 
deaminase (CDA). 
Tetrahydrouridine is a CDA 
inhibitor. A combination of these 






Directly binds to β-like 
globin genes LCR region 
HS3 via its canonical 
binding motif  
  (146) 
NRF2 Stimulation 
Effect on the repressor 
complexes of HBG 





-Bind directly to the LCR 
and HBG promoter 
-Suppression of 




Increase protein levels of SIRT1 (131) 
BCL2L1 Stimulation 
Overexpression of 
BCL2L1 increases HbF 
levels, but the 
mechanism remains 
unclear. It is not clear 
whether this effect is 
direct or indirect. 





Unclear whether this 
effect is direct or 
indirect. It induces HBG 
with TR2 and TR4. 
Overexpression of PGC-
1α induces HBG in 




PGC-1α agonist and Post-
translational modification of PGC-
1α 
(10,150) 
* t-butylhydroquinone; ** dimethyl fumarate; § in clinical trials  











A significant step in the elucidation of the regulation of specific cellular 
processes is associated with the discovery of microRNAs (miRNAs), non-coding 
RNAs 19 to 25 nucleotides in length(4). They target mRNAs in a sequence-
specific fashion and prompt translational suppression or degeneration of the 
target mRNA(4,151,152). Usually, miRNAs target the 3ʹ-UTR of their target mRNAs, 
but they can also bind the 5ʹ-UTR and gene promoter regions(153). In the context 
of HbF and SCD, the presence of miRNAs is associated with the progression of 
globin gene expression, particularly increased HbF synthesis(4). LIN28B is a 
protein targeting the let-7 microRNA family, and its overexpression 
downregulates BCL11A in CD34+ cells from human cord blood(154). Table 1.5 
summarizes the possible roles of some miRNAs in γ-globin regulation. Although 
it remains possible that specific SNPs associated with HbS gene haplotypes 
could interfere with miRNA function by modifying their binding sites in the 3ʹ-UTR 




























on the family 
member 
LIN28B is an RNA-binding 
protein that targets the let-
7 miRNA family. 













miRNA-26B, which inhibits 











Trisomy 13 leads to 
overexpression of miRNA-
15a and 16-1 with a delay 














96 in cord blood CD34+ 
cells leads to a 50% 
decrease in γ-globin 
expression, and its 
knockdown leads to a 20% 
increase in γ-globin 
expression. 
(151) 
Table 1.5. miRNAs associated with the regulation of HBG expression.  


























miR-221 and 222 have a 
role in erythroid 
proliferation and HbF 
synthesis. Their 
overexpression in cord 
blood CD34+ cells 
decreases cell proliferation 
by 70% and HbF synthesis 
by 50%. The knockdown of 
these miRNAs causes an 
increase in cell 





Targets the 3ʹ 
UTR of 
BCL11A XL 
isoform mRNA  
Chr. 8p11 
Overexpression of miRNA-
486-3p decreases BCL11A 














144 decreases NRF2 and 
HbF levels in CD34+ cells 
obtained from healthy 
individuals and patients 
with sickle cell disease.  
miRNA-144 knockdown 











In K562, overexpression of 
miRNA-326 leads to 
reduced KLF1 protein 
levels, which ultimately 
increases HBG expression 
and reduces HBB 
expression. The results 
were not reproducible in 





1.2.7 Treatment for sickle cell disease 
SCD is a multisystem disease that leads to acute and chronic 
complications(2,35). Advances in medical care, early diagnosis and comprehensive 
treatment have led to substantial improvements in the life expectancy of SCD 
patients. In the US and other developed nations, 90% of patients born with SCD 
survive into adulthood (2,35). Nevertheless, even with the best medical care, the 
median survival age remains in the 40s and 50s(48-50). 
 
1.2.7.1 Acute pain management 
Acute pain related to vasoocclusive events is the most common reason 
that SCD patients are hospitalized and seek acute care(161). It usually impacts the 
extremities, back and chest(2,161). The majority of acute pain events can be 
managed at home without the direct involvement of healthcare providers(2); 
however education of patients and parents on when to seek medical help is 
critical(35). Non-steroidal anti-inflammatory drugs and oral opioids usually are 
effective for the alleviation of acute pain(161). Nevertheless, the pathophysiology 
of acute pain in SCD is complex(2,161) and in-home treatment can be 
suboptimal(2). When home management with oral analgesics, hydration and rest 
is unsuccessful, these patients will seek medical attention(2). Once the patient is 
hospitalized, a standardized protocol using a patient’s control analgesia devices 
is indicated. These intravenous infusion pumps (patient-controlled analgesia) 




control and less analgesic use(2). Patients with SCD are frequently hypovolemic 
during acute painful crises due to reduced oral intake, increased insensible 
losses, and reduced renal ability to concentrate urine(162). Hydration may improve 
pain control and reduce the likelihood of other complications(162).  
 
1.2.7.2 Blood and exchange transfusion 
Blood transfusion plays a crucial role in the management and prevention 
of both acute and chronic complications in SCD(35,161). Blood transfusions raise 
the hemoglobin concentration, but more importantly they decrease the HbS 
erythrocyte percentage, suppress HbS synthesis and reduce hemolysis, all of 
which aid in reducing the risk of vaso-occlusion and ischemia(35,161). Blood 
transfusion can be given as a simple or exchange transfusion(35); in the latter, 
there is a synchronous removal and replacement of the patient’s blood with that 
from a HbAA donor (35). Blood exchange transfusion is more effective in 
decreasing HbS concentration and lowering the risk of iron overload(35).  
The main indication for an emergent blood transfusion is severe anemia 
due to aplastic crises (caused by parvovirus B19 infection) or acute sequestration 
crises (splenic or hepatic)(35,161). The goal of this transfusion is to increase 
oxygen carrying capacity, improve blood flow and correct the anemia (35,161). 
Nevertheless, in the management of severe anemia, a simple transfusion should 
be undertaken with caution and the hemoglobin level should be brought up to the 




may cause hyperviscosity related complications(161). The main indication for 
blood exchange transfusion is to manage SCD complications where there is an 
immediate requirement for a significant decrease in HbS percentage, such as in 
ACS, acute stroke, and acute multi-organ failure(35). Chronic (exchange) blood 
transfusion is most commonly used for stroke prevention(35,161). In children, it is 
used to prevent primary stroke for those who have an increased risk as indicated 
by an elevated transcranial doppler velocity of greater than 200cm/s(35) or to 
prevent recurrent stroke(35). 
While blood transfusions can ameliorate many SCD complications(35,161), 
there are downstream effects which limit their long-term use. These include allo-
immunization which can lead to a life threatening delayed hemolytic transfusion 
reaction(35,161). Allo-immunization occurs in 30% of transfused SCD patients 
compared to 2-5% of all transfused recipients(35). Iron overload is another 
complication from chronic blood transfusion and can lead cardiac, hepatic and 
endocrine complications related to iron deposition(35). 
 
1.2.7.3 FDA-approved medications for treatment of sickle cell disease 
In the US, there are currently four medications approved by the Food and 
Drug Administration (FDA) for the treatment of SCD. Hydroxyurea (HU) was 
approved by the FDA in 1998 to treat patients with SCD(2). HU reduces the 
mortality and morbidity related to vaso-occlusive events, anemia, and acute 




multifactorial, including an impact on the kinetics of erythroid differentiation(4-7). 
Additionally, HU has off-target effects that benefit SCD patients, such as increase 
NO production(170) and reduced reticulocytes and neutrophils count(110,170). In 
2017, L-glutamine was approved by the FDA based on a Phase 3 clinical trial 
which demonstrated a reduction in vaso-occlusive crises (VOCs) and 
hospitalizations compared with a placebo after 48 weeks of treatment, followed 
by 3 weeks tapering period and 2 weeks observation period(7). The mechanism of 
action of L-glutamine is unclear , but it is likely due to the replenishment of the 
NAD redox potential and NADPH levels in sickled RBCs(165). In late 2019, 
crizanlizumab and voxelotor were approved by FDA for treatment of SCD(166). 
Crizanlizumab is a monoclonal antibody that targets P-selectin(40). In SCD, P-
selectin in endothelial cells and platelets is upregulated, contributing to the 
pathogenesis of VOC via increased inflammation and adhesion of RBCs to 
endothelial cells(167). Crizanlizumab, given monthly via an intravenous injection, 
significantly reduced the frequency of VOCs during its 52 week long Phase 2 
clinical trial compared to placebo(167). The long-term effects of P-selectin 
blockade remains to be determined(40).  
Voxelotor was approved by the FDA for improvement of anemia in 
patients with HbSS disease. It binds to the α-globin chain(31) and maintains HbS 
in its oxygenated state under hypoxic conditions(168). This hinders the 
polymerization of unmodified deoxy-HbS.(168). Voxelotor increases hemoglobin 




ameliorated in 51% of HbSS patients, the frequencies of VOCs were unchanged 
over 24 weeks of treatment in the Phase 3 trial studying its efficacy(169).  
In summary, HU works primarily by increasing HbF through yet poorly 
understood mechanisms(4-7). Additionally, HU has off-target effects, such as 
increase NO production(170) and reduce neutrophils, reticulocytes and platelets 
production(110,170), which are beneficial in SCD(170). Voxelotor acts by binding to α-
globin chains, thus altering oxygen affinity(40). Voxelotor is the first anti-sickling 
agent (polymerization inhibitor) to be approved by the FDA for the management 
of SCD. L-glutamine and crizanlizumab target pathophysiology of SCD that is 
downstream to deoxy-HbS polymerization. While there is interest in combination 
therapy in the management of these patients, this has yet to be studied in clinical 
trials. Currently, clinicians and patients have more options for the management of 
SCD, but none of these agents is curative and there is much interest in the field 
in developing curative therapies. 
  
1.2.7.4 Potential agents that target HbF expression. 
 
Several pre-clinical compounds are in development that may impact HbF 
expression. One promising HbF-inducing class of agents is the lysine-specific 
histone demethylase 1 (LSD1) inhibitors(10,138). Treatment of SCD mice with RN-1 
(LSD1 inhibitor) increased HbF production and improved multiple aspects of SCD 
pathophysiology (increase in the life span of RBCs, reduction of reticulocyte 




found to induce HbF in both anemic and non-anemic baboons to a level 
comparable to decitabine(137). Similar to decitabine, RN-1 causes DNA 
hypomethylation(137). Recently, more potent LSD1 inhibitors have been identified, 
namely OGL-L002 and GSK-LSD1(138). These LSD1 inhibitors are currently in 
pre-clinical studies. 
Histone deacetylase (HDAC) inhibitors are another potential HbF-inducing 
class of agents(4). Panobinostat (LBH589) is a pan-HDAC inhibitor that shows 
greater than 1000-fold higher potency for HDAC1 and HDAC2 than butyrates 
(butyrate is a known HDAC inhibitor which favors inhibition to HDAC1, HDAC2, 
HDAC3, and HDAC8(139)). In three individuals with Hodgkin’s lymphoma treated 
with panobinostat, HbF levels increased two-fold (139,171). Panobinostat is 
currently being studied in a Phase 1 clinical trial(172).  
Another potential candidate to increase HbF production is a combination 
of decitabine and tetrahydrouridine(4). Decitabine is a nucleoside analog and can 
get incorporated into DNA without terminating chain elongation(4). Unlike other 
nucleoside analogs, such as cytarabine and gemcitabine, the sugar in decitabine 
is unmodified(143-145), leading to inhibition of DNA methyltransferase 1 (DNMT1) 
without cytotoxicity(173). However, decitabine is rapidly metabolized by cytidine 
deaminase, thereby limiting its effect(4). Unfortunately, the metabolites of 
decitabine can be incorporated into DNA and produce cytotoxicity(143). In vivo 
studies have indicated that tetrahydrouridine, a cytidine deaminase inhibitor, 




use of a combination of tetrahydrouridine and decitabine has been completed 
(174), where it was found to be safe and well tolerated by SCD patients(143,174). 
 
1.2.7.5 Hematopoietic stem cell transplantation and gene therapy 
Allogenic hematopoietic stem cell transplantation (HSCT) or bone marrow 
transplant is a curative treatment for SCD patients(35). The majority of HSCT were 
carried out in SCD children with human leucocyte antigen (HLA) compatible 
sibling donors(35). This led to a decline in the incidence of graft versus host 
disease(35). Although, HSCT is curative, there are considerable concerns 
regarding the eligibility criteria for HSCT to limit transplant mortality and long term 
toxicities(35). Additionally, less than 18% of SCD patients have a compatible HLA 
sibling donor(175). 
To overcome the limitation of HLA compatibility, therapeutic ex vivo gene 
transfer of an autologous hematopoietic stem cell can be performed (14,35,175). 
There are multiple approaches that can be undertaken to achieve this goal (176). 
The most commonly used is the self-inactivating lentiviral vector to transfer the 
modified gene into hematopoietic stem cells(14,35). Namely, lentiviral transfer of a 
modified HBB that codes an anti-sickling β-globin variant (T87Q) has been 
reported to be successful in one patient with SCA(175,176).However, 7 other 
patients who were treated with the similar protocol showed non-sustained 
production of the transgenic hemoglobin(176). There are numerous clinical trials 




successful strategy is identified that it will be made available for millions of SCD 
patients living in developing nations(35). The need to identify novel agents for the 
treatment of SCD and its complications remains critical.  
 
1.3 PGC-1 proteins and their physiological effects in humans 
1.3.1 PGC-1 protein family 
Peroxisome proliferator-activated receptor-gamma (PPARγ) coactivator 1, 
or PGC-1, is a family of coactivator proteins that have emerged as key factors in 
regulating various signaling pathways and contributing to both cellular and 
systemic metabolism(12,177). In general, coactivators do not bind DNA directly; 
instead, they bind other transcription factors(178). One key characteristic of the 
PGC-1 family proteins is that they are highly plastic and responsive to external 
environmental factors, which highlights their adaptive functions(177,179). It should 
be noted that the gene nomenclature for the human is PGC-1, and murine is 
Pgc-1. 
PGC-1α, PGC-1β, and PGC-related coactivator (PRC) are members of the 
PGC-1 family(180). PGC-1α was first identified as a protein interacting with PPARγ 
in brown fat tissue and has been the most studied PGC-1 family protein(179,180). 
PGC-1α is now known to regulate several important biological 
processes(178,181,182). PGC-1β is the closest homolog of PGC-1α, and the two 
proteins contain numerous domains with highly similar sequences(180). PRC lacks 




Analysis of the PGC-1 gene family suggests that these genes are conserved 
across various chordate taxa: fish, amphibians, birds, rodents, ruminants, and 
primates(177). 
PGC-1α is involved in regulating cell energy homeostasis and 
metabolism(179,183,184). It plays important roles in the regulation of thermogenesis 
in brown fat tissue(185), ketogenesis and gluconeogenesis in the liver(186), and 
adaptive processes in slow-twitch muscles(187). PGC-1β is known to regulate the 
hepatic synthesis of lipids and lipoproteins(182). In general, a common feature of 
PGC-1 coactivators is their involvement in the induction of mitochondrial 
biogenesis; at the same time, they are associated with metabolic processes that 
enhance tissue oxidative capacity(182). The PGC-1 family proteins have a 
relatively short half-life as they are rapidly ubiquitinated and degraded by 
proteasomes(180).  
 
1.3.2 PGC-1α and mRNA processing 
Although it is known that mRNA processing and transcription occur 
synchronously inside the cell, the specific cellular processes coordinating such 
phenomena are not fully understood(178,188). Structural studies of PGC-1 proteins 
suggest that they contain conserved sequence motifs, which strongly indicates 
that these coactivators are involved in gene expression(188). More specifically, 
these regions include a short arginine/serine-rich domain (RS) and a putative 




domain(178,179,188). The N-terminal domain has two main regions concerning 
activation and repression; both regions contain leucine-rich motifs (LLXXL) and 
are the sites of interaction with transcription factors and other coactivators(178,189). 
According to Lin et al., (2005)(177), PGC-1, in many ways, resembles a typical 
coactivator involved in transcription. Although PGC-1 proteins lack histone 
acetyltransferase activity, the protein can effectively recruit other important 
cofactors (e.g., CREB-binding protein and steroid receptor coactivator-1)(177,178). 
Furthermore, these coactivators have an RNA recognition motif at the C-terminal 
end; these motifs are known to be characteristic of proteins engaged in mRNA 
export or pre-mRNA processing(177,178,188,189). These regions are also homologous 
to the regions found in heterogeneous nuclear ribonucleoproteins (hnRNP), 
which are known to play an important role in different stages of RNA 
metabolism(188). The presence of RRM raises questions about whether PGC-1 is 
involved in one or more aspects of the mRNA processing(188).  
Multiple studies have demonstrated that PGC-1α is indeed involved in pre-
mRNA splicing(188). It can alter splicing patterns(187,189-191); moreover, it is 
associated with RNA polymerase II(178,188). Monsalve et al., (2000)(188) suggests a 
model that hypothesizes the role of PGC-1α in gene transcription. First, a specific 
interaction with DNA-binding transcription factors leads to the recruitment of 
PGC-1α to the regulatory region of the gene of interest(188,192). This recruitment 
leads to a conformational change that allows the interaction of RNA polymerase 




proteins(188,192). These interactions are predicted to lead to transcription 
initiation(188). Second, the C-terminal domain of RNA polymerase II becomes 
heavily phosphorylated and dissociates from the other components; then, a new 
set of proteins, including the mRNA processing machinery, gets recruited to the 
site(188). It is speculated that PGC-1α is associated with recruitment through its C-
terminal domain(188). Finally, PGC-1α dissociates from the DNA-binding 
transcription factors and travels along with the RNA polymerase II complex 
directing the process of transcript(188). Thus, PGC-1α is an essential factor 
affecting multiple biological processes including regulation of transcription and 
metabolism(177,178,183,189). 
 
1.3.3 Physiological role of PGC-1α 
PGC-1α plays an important role in numerous metabolic 
functions(12,184,186,193). It has been demonstrated to be actively involved in 
oxidative muscle transformation (muscle fiber switching from slow oxidative to 
fast oxidative), which is typically induced by exercise or other types of physical 
activity(193). Prolonged exercise is associated with increased PGC-1α mRNA 
levels in skeletal muscle tissues in humans(193). Different types of physical activity 
(e.g., sprinting) are associated with increased PGC-1α gene expression (194).  
Several intracellular signaling pathways such as reactive oxygen species 
(ROS) signaling, mitogen-activated protein kinase (MAPK) signaling, and 




involved in stimulating physical exercise-induced PGC-1α expression(182,195). 
Several different splice variants of the PGC-1α gene localized in skeletal muscles 
have been identified(178,187,189,190). Depending on the specific splice variant 
(particularly concerning the presence of the starting exon), the tissue may 
produce a normal protein (PGC-1α) or its truncated version(178,189,190). Oxygen 
deprivation is often associated with the expression of the truncated form of the 
protein(195). In mice, overexpression of Pgc-1 in the heart, skeletal muscles, and 
white fat tissue is associated with increased biogenesis in mitochondria(195). This 
process is initiated by Pgc-1 by triggering the expression of NRF-1 and NRF-2, 
nuclear respiratory factors responsible for the regulation of mitochondrial 
proteins(195).  
PGC-1α regulates gluconeogenesis in the liver during the fasting 
response(195) via the binding of PGC-1α to the FoxO1 and HNF4α 
receptors(186,195). Upregulation of PGC-1α in models of diabetes mellitus, 
characterized by elevated gluconeogenesis, strongly suggests the important role 
of PGC-1α in the regulation of blood glucose levels(12). A partial reduction in 
PGC-1α levels in heterozygous knockout mice has been associated with 
immediate and severe failure of gluconeogenesis, suggesting that PGC-1α plays 
a role in glucose metabolism and regulation(186).  
Regulation of PGC-1α is fine-tuned by multiple post-translational 
modifications involving numerous enzymes and pathways(182). Phosphorylation 




stability(182). In skeletal muscle cell culture, phosphorylation of PGC-1α through 
the AMPK pathway enhances PGC-1α mitochondrial oxidative 
metabolism(182,196). Acetylation is another post-translational modification affecting 
PGC-1α activity(182). In general, acetylation inhibits the transcriptional activity of 
PGC-1α and prevents it from binding to other transcription factors(182). In contrast, 
deacetylation by SIRT1 activates PGC-1α, but phosphorylation through AMPK 
signaling is required(182). This suggests that PGC-1α is regulated through a 
combination of different post-translational modifications. 
 
1.3.4 PGC-1 α and β in erythropoiesis 
Recent evidence suggests that these proteins also play an important role 
in the maturation and survival of erythroid cells(197). In murine models, Pgc-
1α/Pgc-1β mutants are incapable of expressing sufficient globin mRNA and 
suffer from anemia and stunted growth(197). To date, Cui et al., (2014)(197). Have 
conducted the most comprehensive evaluation of the role of Pgc-1α and Pgc-1β 
in erythropoiesis in mice; however, similar data are lacking in humans(197). Pgc-
1α and Pgc-1β are expressed differently during the advanced stages of 
embryonic development(197). Pgc-1α is most strongly expressed during the earlier 
(embryonic) stages, reaching its maximum concentration after the primitive-to-
definitive erythropoiesis switch occurs (embryonic day 14.5 in mice)(197). This is 
when the process of erythropoiesis moves from the yolk sac to the 




contrast, Pgc-1β expression minimally changes throughout murine embryonic 
development(197). 
A study involving individual and combined loss-of-function mutations in 
Pgc-1 genes demonstrated that Pgc-1α/Pgc-1β double-mutant mice had 
significantly reduced expression of embryonic globins when measured at 
embryonic day 10.5 (yolk-sac stage) compared to WT mice(197). Importantly, the 
function of the genes appeared to span across both primitive (yolk sac) and 
definitive (spleen and bone marrow) stages of erythropoiesis(197). Quantitative 
reverse transcription-PCR was utilized to study and measure the potential effects 
of Pgc-1α and Pgc-1β on globin expression patterns and physiological functions. 
Analysis of blood samples from Pgc-1α/Pgc-1β double-mutant pups suggested 
that, in comparison with WT animals, various multi-lineage hematopoietic 
deficiencies (e.g., leukopenia, increased number of nucleated erythrocytes, and 
thrombocytopenia) occurred (197). Moreover, a significant deficiency of embryonic 
βh1-globin and adult α-globin was observed. Although mutations in either Pgc-1α 
or Pgc-1β were associated with severe negative consequences regarding 
erythropoiesis, the effect was even more pronounced in the case of double 
mutants(197). This observation suggests that Pgc-1α and Pgc-1β have 
compensatory or complementary functions, where both genes interact to regulate 
complex processes such as erythropoiesis(197). 
Cui et al., (2014)(197) used hematoxylin and eosin staining to demonstrate 




and large lipid droplets) occur in the spleen and liver of the studied Pgc-1 double-
mutants(197). Moreover, flow cytometry analysis demonstrated that mutant Pgc-1 
mice had a decreased number of mature erythrocytes in their bone marrow and 
spleen, suggesting that both Pgc-1α and Pgc-1β are involved in the RBC 
maturation process(197). PGC-1α and PGC-1β, together with other nuclear 
receptors (e.g., TR2 and TR4), bind the globin gene promotor areas and are 
involved in regulating the development and proliferation of fetal globin genes as 
well as erythropoiesis in general(150). Both, PGC-1α and PGC-1β interact with the 
TR4 receptor and initiate its transcriptional activation(197). These data suggest 
that both PGC-1α and PGC-1β are involved in erythropoiesis via interaction with 
the TR4 receptor(150,197). Thus, both of these receptors and their interaction with 
PGC-1α can be characterized as promising targets for clinical research targeting 
different types of hemoglobinopathies (such as β-thalassemia and sickle cell 
anemia)(150,197). However, significant research gaps remain; for example, the 
effect of post-translational modifications of PGC-1α in erythrocyte or hemoglobin 
regulation has not been studied. 
 
1.4 Rationale, hypothesis, and specific aims 
 SCD is a monogenic disorder with multi-organ involvement due to a 
complex, diffuse vasculopathy(2,4). Patients with SCD suffer from recurrent 
episodes of VOCs precipitated by deoxy-HbS polymerization leading to 




SCD(1). HU is an FDA-approved drug for the management of SCD(4). HU induces 
HbF synthesis through multifactorial mechanisms(4-7). Although many patients on 
HU exhibit a reduced frequency of VOCss and consequently, reduced 
hospitalizations, approximately 10-15% of patients experience no significant 
clinical improvement(8). Additionally, there are numerous patient and physician-
related factors that limit utilization(9). Therefore, it is important to identify new 
therapeutic agents that can induce HbF synthesis, particularly those that act by 
mechanisms different from HU, thus making it possible for combination therapy 
with HU. Recently, PGC-1α has been shown to enhance γ-globin gene 
transcription(10). Forced overexpression of PGC-1α in erythroid progenitors 
obtained from Lin- cells from SCD transgenic mice induced γ-globin 
expression(10).  
We hypothesized that modulation of PGC-1α activity enhances HbF 
synthesis, thereby potentially alleviating the pathophysiological effects of SCD. 
To investigate this hypothesis, this thesis has three specific aims: Aim 1: 
To examine the effect of PGC-1α overexpression and knockdown in primary 
human CD34+ derived erythroid cell culture, Aim 2. To examine the effect of 
PGC-1α modulator compound(s) in primary human CD34+ derived erythroid cell 
culture and Aim 3. To examine the in vivo effects of PGC-1α modulator 







CHAPTER II: Materials and methods 
2.1 Primary human CD34+ derived erythroid cell culture 
Human CD34+ cells were purified from the peripheral blood of de-identified 
healthy volunteers. In brief, 10 mL peripheral blood was collected in EDTA tube 
then blood components were separated using Ficoll-Opaque, and CD34+ cells 
were selectively isolated from the peripheral blood mononuclear cell fraction 
using anti-CD34+ antibody-conjugated microbeads and mini-MACS column, 
according to the manufacturer’s instructions (Miltenyi Biotech #130-100-453). 
CD34+ cells were cultured in an expansion phase, followed by a three-phase 
culture system(135,199). During the expansion phase, CD34+ cells were expanded 
in StemSpanTM SFEM II medium (StemCell Technology) supplemented with 
StemSpanTM CD34+ Expansion Supplement (StemCell Technology #02691) for 
4-5 days at a density of 1 × 105 cells/mL. During the first phase (day 0 to 7 after 
expansion), CD34+ cells were cultured in an erythroid differentiation medium 
(EDM). The basic components of EDM are Iscove's Modified Dulbecco's Medium 
(IMDM) with 1% L-glutamine; 2% penicillin-streptomycin; 330 µg/mL Holo-human 
transferrin (Sigma #T0665); 10 µg/mL recombinant human insulin (Sigma 
#I9278); 2 IU/mL heparin (Sigma #H3149); 5% heat-inactivated human 
peripheral blood plasma (Stem cell technology #70039.6); and 3 IU/mL 
Erythropoietin (Amgen; EPO). During phase 1, EDM was supplemented with the 
following components: 1 x 10-5 M hydrocortisone (Sigma #H0135), 100 ng/mL 





IL-3 (StemCell Technology #78146). During phase 2 (day 7 to 11), EDM was 
supplemented with 100 ng/mL hSCF. During phase 3 (day 11 to 18), EDM was 
used without any additional supplements. Cells were maintained at a density of 2 
× 10 5 cells/mL in phase 1 and 2 cultures, and 0.5–1 x 10 6 cells/mL in the phase 
3 culture. 
For PGC-1α agonist experiments, human peripheral blood CD34+ derived 
erythroid cells were treated with 1, 5, and 10 µM of ZLN005 (Cayman Chemical 
#14121) or SR-18292 (Cayman Chemical #22084) on Day 4 of culture and 
harvested on Day 13. HU (Cayman Chemical #23725) at 25 µM was used as a 
positive control. 
 
2.2 Culture of human umbilical cord-derived erythroid progenitor (HUDEP-
1) cell 
HUDEP-1 cells(200) were cultured in StemSpanTM SFEM I medium 
(StemCell Technology #09650) with 50 ng/mL hSCF, 1 M dexamethasone (MP 
Biomedicals #190040), 1 g/mL doxycycline (Fisher Scientific #AAJ67043AD), 3 
U/mL EPO, and 1% L-glutamine. HUDEP-1 cells are maintained undifferentiated 
in this culture system. Cells were treated with 2.5, 5, 7.5 and 10 µM of ZLN005 or 
100 µM HU as positive control for 2 days and then harvested for FACS and RT-






2.3 Preparation for lentiviral particles 
293T cells were seeded in 10 cm tissue culture dish coated with collagen I 
(Corning #354450) in Dulbecco’s modified Eagle’s medium (DMEM) (Corning 
#15018CV) supplemented with 10% Fetal Bovine Serum (FBS) (Gibco 
#16140071), 1% penicillin-streptomycin (Gibco #10378016), and 1% L-glutamine 
(StemCell technology #07100). When cells reached to 80-90% confluency, a 
mixture of packaging plasmids (PMD2.G and psPAX2) and PGC-1α 
overexpression or knock-down plasmid with Lipofectamine 3000 (Invitrogen 
#L3000008) was added into the culture according to manufacturer’s instruction of 
transfection. Six hours post plasmid transfection, the medium was changed. The 
supernatant (containing lentivirus) was collected at 24 h and 48 h post plasmid 
transfection and concentrated using a Lenti-X concentrator (Takara #631231). 
Viral titers were measured using Lenti-X Go Stix plus (Takara #631280). 
The lentiviral vector used for PGC-1α overexpression was a pLVX-
TetOne-Puro vector (Takara #631849) containing the Tet-on inducible element 
and the puromycin resistant gene. PGC-1α was sub-cloned into this vector at the 
multiple cloning site using restriction enzyme BstZ17I (amino acid position 2516) 
and BamHI (amino acid position 2496) and driven by the TRE3GS promoter. An 
empty vector backbone was used as a control.  
The lentiviral vector used for PGC-1α knock-down was pLV-shRNA-
EGFP/Puro-U6 vector (VectorBuilder #VB151023-10034) that contains a U6 





sequence used. It also has EGFP:T2A: puro sequence for selection which is driven 
by the hPGK promoter. Lentivirus with a scrambled shRNA sequence was used as 






2.4 Lentiviral transduction of primary human CD34+ derived erythroid cells 
Transduction of primary human CD34+ derived erythroid cells was 
performed on Day 1 of the first phase. Cells were seeded in 96-well plates (4 × 
104 cells per well) containing phase 1 medium that contained 5 µg/mL polybrene, 
and lentiviruses were added to the culture at a concentration of the multiplicity of 
infection (MOI) of 50. Six hours after transduction, the supernatant was 
discarded, and the cells were re-seeded in a 6-well plate with fresh phase 1 
medium. On day 4, puromycin (2 µg/mL) and doxycycline (1 µg/mL, only for 
inducing the overexpression of PGC-1α) were added to the medium for selection 
of infected cells. The medium was replaced every 1–2 days to remove the dead 
cell debris resulting from puromycin selection in the following days. Figure 2.2 
shows the experimental plan for human peripheral primary erythroid progenitor 
CD34+ cells culture and lentiviral transduction time. 
 










Figure 2.2. Experimental scheme depicting the three-phase culture system 
for primary human CD34+ derived erythroid cells and lentiviral 
transduction.  
CD34+ cells were cultured in the expansion phase for 4-5 days and then cultured 
in the three-phase differentiation media. In each phase, a component or two were 
excluded to allow the cells to differentiate. Lentivirus transduction and puromycin 
selection are performed at D1 and D4, respectively. 
 
2.5 Drug preparation 
ZLN005 and SR-18292 were purchased from Cayman Chemical (#14121 
and #22084, respectively). For cell culture experiments, both agents were 
prepared in DMSO as a 20 µM stock solution. Further dilution was done in 
DMSO to the desired working solution. Both agents are organic compounds, and 
they are insoluble in PBS. The maximum concentration in the culture 





precipitate in the culture. Hydroxyurea was used as a positive control for these 
experiments.  
For the mouse in vivo experiments, ZLN005 was re-suspended using 2-
hydroxypropyl-β-cyclodextrin (HP-β-CD) (Cayman Chemical #16169), which is a 
cyclic oligosaccharide that improves the solubility of organic compounds with a 
phenyl group(201,202). This step improved the solubility of ZLN005 in PBS up to 10-
fold, which was sufficient to conduct in vivo experiments. The chemical HP-β-CD 
is very stable and safe to use in mice(201,202). 
 
2.6 Surface and intracellular staining for flow cytometry  
5 x 105 cells were harvested and washed with cold before staining with 
allophycocyanin (APC)-conjugated anti-CD235a (BioLegend #349114) and 
BV421-conjugated anti-CD71 (BioLegend #113813) antibodies, followed by an 
incubation period of 20 min in ice. Cells were washed with PBS, containing 
0.01% bovine serum albumin (BSA). Next, the cells were fixed and permeabilized 
using BD Cytofix Fixation Buffer (Biosciences #554655), according to the 
manufacturer’s instructions. Then, the cells were stained with 5 µL fluorescein 
isothiocyanate (FITC)-conjugated anti-HbF antibody (ThermoFisher #MHFH01) 
for 30 min in the dark on ice.  
For PGC-1α knock-down experiments, Pacific blue-conjugated anti-
CD235a (BioLegend #349108) and Phycoerythrin (PE)-conjugated anti-CD71 





conjugated anti-HbF antibody (ThermoFisher #MHFH05) was used for HbF 
intracellular staining.  
Spectrum compensation was done using single stained UltraComp eBeads 
(ThermoFisher #01-2222-41). For F-cells measurement, cells were gated from 
CD235a+ populations.  
For the differentiation assay, cells were stained in a separate tube using 
an APC-conjugated anti-CD233 antibody (American Research product #08-9439-
6) and BV421-conjugated anti-CD49d antibody (BioLegend #304322). 
For the PGC-1α agonist experiments, cells were washed with cold PBS, 
stained with Zombie NIR (BioLegend #423106) following the manufacturer's 
instructions. Cells were washed with PBS containing 0.01% BSA and stained 
with APC-conjugated anti-CD235a (BioLegend #349114) and BV421-conjugated 
anti-CD71 (BioLegend #113813) antibodies and incubated on ice for 20 min. 
Cells were washed with PBS containing 0.01% BSA. Next, the cells were fixed 
and permeabilized using BD Cytofix Fixation Buffer (Biosciences #554655), and 
stained with 5 µL FITC-conjugated anti-HbF antibody (ThermoFisher #MHFH01) 
for 30 min in the dark on ice. Flow cytometry was performed on fluorescence-
activated cell sorting (FACS) LSRII (BD), and data were analyzed using FlowJo 






2.7 Transgenic SCD mice 
Eight-week-old transgenic SCD mice were purchased from Jackson 
Laboratory (stock #013071). These hα/hα::βS/βS mice, homozygous at the Hba 
locus of the human α-globin (Hbatm1(HBA)Tow) and homozygous at the Hbb locus of 
the human Aγ-globin and sickle βS-globin (Hbbtm2(HBG1,HBB*)Tow), are referred to as 
the Townes model(203,204). Mice were intravenously injected daily in a tail vein with 
ZLN005 (Cayman #14121) for four continuous weeks. Blood was collected via 
tail bleed after two and four weeks of treatment. There were three groups of 
mice, the vehicle control group, 1µg/g and 10µg/g ZLN005 treated groups. Each 
group contained three mice. At 10µg/g ZLN005, progressive necrosis of the tail 
was observed, and experiments with that dose had to be terminated at 2 weeks’ 
time. 
 
2.8 Mouse blood cell surface staining 
Whole blood (5 µL) obtained from the mice was washed with 1 mL PBS-
0.1% BSA. The cell pellet was resuspended with 100 µL PBS-0.1% BSA. Since 
the sample is whole blood, mouse Fc blocker (TruStain FcX Plus; BioLegend 
#156604) was used to block white blood cells by nonspecific binding of antibody 
Fc region with white blood cells Fc receptor. Samples were incubated for 5 min 
on ice. BV421 anti-mouse CD71 antibody (BioLegend #113813) and APC anti-





being incubated for 20 min on ice. The samples were washed twice with PBS-
0.1%BSA and were subjected to flow cytometry analysis. 
 
2.9 Mouse blood HbF staining 
Mouse whole blood (10 µL) was fixed in 1 mL cold 0.05% glutaraldehyde 
for 10 min at room temperature. The sample was spun down and washed three 
times with 1 mL PBS-0.1% BSA. The cell pellet was resuspended, by vortexing, 
in 0.5 mL 0.1% triton X-100, and incubated for 5 min at room temperature. Next, 
it was washed twice with 1 mL PBS-0.1% BSA. The cell pellet was then 
resuspended in 0.5 mL PBS-0.1% BSA. An aliquot of 10 µL was transferred to a 
new tube, 5 µL of HbF FITC antibody (ThermoFisher #MHFH01) was added, and 
a total volume of 100 µL was made up with PBS-0.1% BSA. The mixture was 
incubated for 30 min on ice. Finally, the samples were washed three times with 
PBS-0.1BSA and they were subjected to flow cytometry analysis.  
 
2.10 Mouse reticulocyte staining 
Thiazole orange was utilized to stain mice reticulocytes(205). A stock 
solution of 0.4 µM thiazole orange was prepared by dissolving 1 mg of thiazole 
orange in 1 mL methanol. The stock solution was stored in a dark glass bottle (as 
thiazole orange can stick to plastic surfaces but not glass)(205) at -20°C in the 
dark. A working solution, stable for 1 week at 4°C was made by adding 6 µL of 





orange, and the mixture was incubated for 90 min at room temperature to 
prepare for analysis(205) in LSRII using blue laser 488 nM and 530/30 filter. 
 
2.11 RNA extraction and reverse transcription-quantitative PCR 
 RNA was extracted from the cells using TRIzol reagent (ThermoFisher 
#15596026). In brief, 1 × 106 cells were pelleted down, 1 mL TRIzol reagent was 
added, and the tube was vortexed until the cell pellet dissolved. Then, 0.2 mL 
chloroform was added; the tube was inverted 5-6 times and centrifuged at 12,000 
g for 15 min at 4°C. The upper phase (containing RNA) was then transferred into 
a fresh tube. An equal volume of isopropanol and 20 µg glycogen (Invitrogen 
#10814010) were added, and the tube was centrifuged at 12,000 g for 15 min at 
4°C. Then, the pellet was washed with 70% ethanol and centrifuged at 12,000 g 
for 5 min at 4°C. The supernatant was removed, and the pellet air-dried for 5–10 
min. Finally, the pellet was resuspended in 20 µL RNase-free water. RNA 
quantity and quality were measured using NanoDrop 2000 spectrophotometer 
(ThermoFisher).  
A two-step reverse transcription-quantitative PCR (RT-qPCR) was used. 
First, cDNA synthesis was performed using SuperScript™ IV VILO™ Master Mix 
with ezDNase (ThermoFisher #11766050) following the manufacturer’s protocol.  
We determined that cDNA synthesis is critical and should be performed 
immediately after extracting the RNA to enable PGC-1α mRNA to be detected. 





for total cDNA synthesis is 25 min. The reverse transcriptase enzyme in this kit 
works at 50°C. PGC-1α mRNA in primary human CD34+ derived erythroid cells 
using the traditional cDNA kits could not be detected. mRNA secondary structure 
could terminate reverse transcriptase enzyme activity(206). Traditional cDNA 
synthesis kits include a reverse transcriptase enzyme that works at 37–42°C, 
which may not be ideal in the case of PGC-1α mRNA to create a secondary 
structure that inhibits reverse transcriptase activity. Therefore, a higher 
temperature is needed to linearize the mRNA for the RT enzyme to work.  
PowerUp SYBR green master mix (ThermoFisher #A25742) was used to 
determine HBB and HBG mRNA and PGC-1α mRNA levels and the expression 
levels were normalized to OAZ1 mRNA expression. The primers used are 







TaqMan primers from ThermoFisher were used to determine the 
expression levels of genes presented in Table 2.2. TaqMan fast advanced 
master mix (ThermoFisher #4444556) was used for this protocol. OAZ1 was 
used as a housekeeping gene.  
Name Sequence 5’ to 3’ 
PGC-1α F TCAGACCTGACACAACACGG 
PGC-1α R GCGTCCACAAAAGTACAGCTC 
HBB F AAGGGCACCTTTGCCACA 
HBB R GGTGAATTCTTTGCCAAAGTGAT 
HBG F GATGCCATAAAGCACCTGGATG 
HBG R CGAAATGGATTGCCAAAACGG 
OAZ1 F ATGGTGAAATCCTCCCTGCA 
OAZ1 R GACCCGGGTTACTACAGCA 










For the in vivo mice experiments, PowerUp SYBR green master mix 
(ThermoFisher #A25742) was used. Mouse knock-in HBG and HBB mRNA 
expression was determined (primers in Table 2.1) and were normalized to mOAZ1 
mRNA expression. βh1, εy, and mPGC-1α were determined using the same 
method (Table 2.3). Mouse OAZ1 was used as a housekeeping gene for 










Gene Primers Gene Primers 
KLF1 Hs00610592_m1 MYB Hs00920556_m1 
SIRT1 Hs01009006_m1 LSD1 Hs01002741_m1 
ZBTB7A Hs00792219_m1 OAZ1 Hs00427923_m1 
BCL11A Hs01093197_m1   









Table 2.3. Murine quantitative RT-PCR primers 
 





2.11 Statistical analysis 
Results are presented as the mean ± standard deviation of at least three (n 
= 3) independent biological replicates. More details about the sample size have 
been provided in the figure legends. All statistical analyses were calculated using 
the Student t-test. p≤ 0.05 was considered to be statistically significant. The exact 



















CHAPTER III: Effect of PGC-1α on F-cell expression in primary human 
CD34+ derived erythroid cells in vitro 
3.1 HYPOTHESIS 
 In 2015, Cui and colleagues reported that Lin– progenitor cells isolated 
from bone marrow in 6-9 week old transgenic SCD mice (Townes model)(10), 
were induced to undergo terminal erythroid differentiation in vitro(10). 
Transduction with adenovirus expressing PGC-1α or GFP (control) was done on 
Day 1 of culture. Cultures with adenovirus expressing PGC-1α showed significant 
induction of γ-globin mRNA (4-fold and 6-fold increase, on Days 2 and 4, post-
transduction, respectively) when compared to cultures transduced with GFP 
adenovirus(10). However, to date, no such studies have been conducted in normal 
human erythroid cells. 
In this chapter, we will test these hypotheses; PGC-1α has an essential 
role in HbF expression in primary human CD34+ derived erythroid cells in vitro, 
and that this effect is mostly independent of alteration in erythroid cell 










1. To assess the effect of PGC-1α over-expression upon the production of 
F-cells in primary human CD34+ derived erythroid cells in vitro. 
2. To determine the effect of PGC-1α over-expression in primary human 
CD34+ derived erythroid cells in vitro upon; a) Erythroid cell differentiation and b) 
The levels of known major transcriptional factors regulating HbF expression. 
3. To evaluate the effect of PGC-1α down-regulation upon the production 
of F-cells in primary human CD34+ derived erythroid cells in vitro. 
4. To determine the effect of PGC-1α down-regulation in primary human 
CD34+ derived erythroid cells in vitro upon; a) Erythroid cell differentiation and b) 
Levels of known major transcriptional factors regulating HbF expression. 
If successful, primary human CD34+ derived erythroid cell culture in vitro 
can become a useful experimental platform to test for the effect of PGC-1α 
agonists, thereby laying the foundation for the search of small molecules capable 










3.3.1 PGC-1α overexpression in primary human CD34+ derived erythroid 
cell culture led to elevated F-cell expression 
Primary human CD34+ derived erythroid cells were cultured in a three-
phase culture system. In phase 1, the erythroid cells were transduced with 
lentivirus particles on Day 1, and puromycin and doxycycline (PGC-1α 
overexpression lentivirus vector is a teton vector, as described in Chapter II, 
Section 2.3) were added on Day 4, and harvested on day 13 (phase 3), as 
described in Chapter II, Section 2.4.  
Figure 3.1A demonstrates that PGC-1α mRNA levels were markedly 
increased (345 ± 103-fold) in cultures transduced with PGC-1α overexpression 
lentivirus particles compared to untreated cultures and cultures transduced with 
empty vector lentivirus particles. Furthermore, in cultures transduced with PGC-
1α overexpression lentivirus particles, there was a significant increase in F-cells 
percentage to 36.5 ± 3.1%, compared to cultures transduced with empty vector 
lentivirus particles (7.9 ± 3.3%) and untreated cultures (10 ± 8.4%) (Figures 3.1B 
and C). 
γ-globin mRNA expression level was also significantly increased (18.8 ± 
8.5-fold) in cultures transduced with PGC-1α overexpression lentivirus particles 
compared to cells in untreated cultures and cultures transduced with empty 







Figure 3.1. PGC-1α mRNA, F-cells, and γ-globin mRNA expression in 
primary human CD34+ derived erythroid cell culture transduced with PGC-
1α overexpression lentivirus particles. 
A) PGC-1α mRNA levels as determined by RT-qPCR in untreated culture, culture 
transduced with empty vector lentivirus particles, and culture transduced with 
PGC-1α overexpression lentivirus particles (n=3). The PGC-1α mRNA levels 
found in cultures transduced with a PGC-1α overexpression lentivirus is markedly 
increased to 345 ± 103-fold of that found in either control cultures. B) Flow 
cytometry profiles of a representative experiment showing F-cells % in two 
control cultures, one untreated and the other transduced with empty vector 





lentivirus particles. Cells were gated on CD235a, a marker for erythroid cells. The 
culture transduced with PGC-1α overexpression particles had 34.8 % F-cells, 
compared to 10.9% and 7.39% in the two control cultures. C) Summary of flow 
cytometry data of F-cell % generated from cultures with CD34+ cells from 5 
different individuals (n=5). Those cultures transduced with PGC-1α 
overexpression lentivirus particles had 34.8 ± 3.1% F-cells, significantly higher 
than the two control cultures, 10.0 ± 8.4% (p= 0.0002) and 7.9 ± 3.3% (p= 
0.000001). D) The expression of γ- and β-globin mRNA was determined using 
RT-qPCR in untreated cultures, cultures transduced with empty vector lentivirus 
particles, and cultures transduced with PGC-1α overexpression lentivirus 
particles. In three independent experiments (n=3), cultures transduced with PGC-
1α overexpression lentivirus particles showed significantly higher γ-globin mRNA 
expression (18.8 ± 8.5-fold) than untreated cultures and cultures transduced with 
empty vector lentivirus particles. There is a pattern of increase β-globin mRNA 
expression in cells with PGC-1α overexpression (9.8 ± 4.9-fold) higher than that 
in control cells, but this was not statistically significant (p=0.06). There were 
insufficient cells in each culture to undertake all three measurements (PGC-1α 
mRNA, % of F-cells, and globin mRNA). Thus, results for panels A, C, and D 
were obtained from cultures from different subjects. The experiment condition 
and methodology were identical (same lentivirus multiplicity of infection, 
puromycin selection dose and duration, and harvest time; as described in the 





overexpression. NS; not statistically significant. P-values: *=0.05; **= 0.01; 
***=0.0002; ****=0.000001. 
 
3.3.2 The effect of PGC-1α overexpression on the differentiation kinetics in 
primary human CD34+ derived erythroid cell culture 
Erythroid cellular differentiation markers (CD235a/CD71) and markers of 
cellular terminal differentiation (CD233/CD49d)(207) were determined using flow 
cytometry in cells obtained from cultures transduced with PGC-1α 
overexpression lentivirus particles, cultures transduced with empty vector 
lentivirus particles and untreated cultures on Day 13 (Figure 3.2).  
Hu et al., (2013)(207) used terminal differentiation markers (CD233/CD49d) 
to sort erythrocytes at different stages. The expression of CD49d decreases 
gradually during late stages of terminal erythroid differentiation while CD233 
expression progressively increases during the terminal differentiation(207). CD233-
/CD49d+ cells are proerythroblast(207). CD233+/CD49d+ cells can be further 
subdivided into the following; CD233low/CD49dhigh are early basophilic 
erythroblast, CD233med/CD49dhigh are late basophilic erythroblast, 
CD233med/CD49dmed are polychromatophilic erythroblast and CD233high/CD49dlow 
are orthochromatic erythroblast(207). According to Hu et al., (2013) the majority of 
cells on Day 14 of culture are CD233+/CD49d+. In our experiments, Day 13 is the 





there is any effect on terminal differentiation profile in primary human CD34+ 
derived erythroid cell culture.  
Figure 3.2. The effects of PGC-1α overexpression on differentiation 
(CD235a/CD71) and terminal differentiation (CD233/CD49d) in primary 
human CD34+ derived erythroid cell culture.  
A) Flow cytometry profiles of a representative experiment for untreated cells, 
cells transduced with empty vector lentivirus particles, and cells transduced with 





antibodies and BV421-labeled CD71 antibodies. B) Flow cytometry profiles of a 
representative experiment for untreated cultures, cultures transduced with empty 
vector lentivirus particles, and cultures transduced with PGC-1α overexpression 
lentivirus particles were stained with APC-labeled CD233 antibodies and BV421-
labeled CD49d antibodies. C) This graph summarizes the results for % of 
CD235a+/CD71+ cells and % of CD233+/CD49d+ cells from five independent 
experiments (n = 5). There was no statistically significant difference between 
cultures with PGC-1α overexpression (98.9 ± 0.4% of CD235a+/CD71+ cells, and 
73.7 ± 17.3% of CD233+/CD49d+cells) compared to cultures transduced with 
empty vector lentivirus (98.2 ± 0.7% and 67.1 ± 24.3%, respectively), and 
untreated cultures (98.4 ± 0.6% and 61.4 ± 17.7%, respectively). NS; not 














3.3.3 The effect of PGC-1α overexpression on mRNA expression levels of 
known major transcriptional factors regulating HbF expression in primary 
human CD34+ derived erythroid cell culture 
Cultures transduced with PGC-1α overexpression lentivirus particles have 
a significant increase in MYB mRNA expression (2.6 ± 0.6-fold) and a significant 
reduction in BCL11A and ZBTB7A mRNA expression (0.4 ± 0.1-fold and 0.5 ± 
0.1-fold, respectively) compared with cultures transduced with empty vector and 
untreated cultures (Figure 3.3). 
 
 
Figure 3.3. The effects of PGC-1α overexpression on the mRNA expression 
levels of known major transcriptional factors regulating HbF expression in 
primary human CD34+ derived erythroid cells. 
RT-qPCR was used to determine the mRNA expression levels for 6 major 
transcriptional factors in regulating HbF, in untreated cultures, cultures 





PGC-1α overexpression lentivirus particles (n=3). MYB expression in cultures 
transduced with PGC-1α overexpressing lentivirus particles was significantly 
higher (2.6 ± 0.6-fold) than that in untreated cells and cells transduced with 
empty lentivirus particles. Additionally, cultures transduced with PGC-1α 
overexpression lentivirus particles showed significantly lower BCL11a and 
ZBTB7A expression (0.4 ± 0.1-fold and 0.5 ± 0.1-fold, respectively) than 
untreated cultures and cultures transduced with empty vector lentivirus particles. 
There were no statistical differences in the mRNA expressions of LSD1, KLF, 
and SIRT1 between samples. NS; not statistically significant. P-values; * = 0.01, 
** = 0.006, *** = 0.001. 
 
3.3.4 PGC-1α knockdown has no effect on F-cell expression in primary 
human CD34+ derived erythroid cells 
PGC-1α knockdown experiments were conducted with a similar approach 
to that used for PGC-1α overexpression. However, the lentivirus cassette for 
knockdown contains GFP. Therefore, minor changes were made for flow 
cytometry experiment, previously described in Chapter II, section 2.6.  
In three experiments, cultures transduced with the PGC-1α shRNA 
lentivirus showed significantly lower PGC-1α mRNA expression (0.4 ± 0.2-fold) 
than untreated cultures and cultures transduced with scramble shRNA (Figure 





mRNA expression in cultures transduced with PGC-1α shRNA when compared 
with culture transduced with scramble shRNA (Figure 3.4D).  
Another four independent experiments (n=4) were conducted to measure 
the percentage of F-cells on Day 13. No significant difference was found in % of 
F-cells between cultures transduced with PGC-1α shRNA (7 ± 3.8%) compared 
to untreated cultures and cultures transduced with scramble shRNA (Figure 
3.4B, C). 
 
Figure 3.4. PGC-1α mRNA and F-cells expression in primary human CD34+ 
cells derived erythroid cell culture transduced with PGC-1α shRNA 
lentivirus particles. 
A) RT-qPCR data from three independent experiments (n=3) shows a significant 





lentivirus particles (0.4 ± 0.2-fold) compared with untreated cultures and cultures 
transduced with scramble shRNA lentivirus particles. There was no statistically 
significant difference in PGC-1α mRNA expression between cultures transduced 
with scramble shRNA and untreated cultures. B) Flow cytometry profile of a 
representative experiment shows the % of F-cells, after gating on CD235a+, in 
untreated cultures, cultures transduced with scramble shRNA lentivirus particles, 
and cultures transduced with PGC-1α shRNA lentivirus particles. Both 
transduced cultures were under puromycin selection pressure. The culture with 
PGC-1α shRNA had 3.41% F-cells, compared to 7.83% and 7.53% in untreated 
and scramble shRNA transduced cultures, respectively. C) In four independent 
flow cytometry experiments (n=4), there was no statistically significant difference 
found in the % of F-cells between cultures transduced with PGC-1α shRNA (7.3 
± 3.8%), untreated culture (8 ± 1.8%) and culture transduced with scramble 
shRNA (12 ± 3.4%). D) γ- and β-globin mRNA expression was determined by 
RT-qPCR in untreated cells, cells transduced with scramble shRNA lentivirus 
particles, and cells transduced with PGC-1α shRNA lentivirus particles (n=3). 
There was no statistically significant difference in γ-globin with PGC-1α 
knockdown (2.1 ± 0.2-fold) compared to cells transduced with scramble shRNA 
and no significant difference in β-globin mRNA expression between cells with 
PGC-1α shRNA (1.4 ± 0.3-fold) and cells transduced with scramble shRNA. 
However, there was a significant difference in γ-globin mRNA expression 





untreated cultures. NS; not statistically significant. (un); untreated. (scr); 
scramble shRNA. P-values; * = 0.02, ** = 0.005, *** = 0.002, **** = 0.0004 
 
3.3.5 The effect of PGC-1α knockdown on primary human CD34+ derived 
erythroid cell differentiation (CD235a/CD71) and terminal differentiation 
(CD233/CD49d) 
Primary human CD34+ derived erythroid cells differentiation kinetics was 
determined using flow cytometry in four independent cultures (n=4). In cultures 
transduced with PGC-1α shRNA lentivirus particles, there was no significant 
difference in the percentage of CD235a+/CD71+ cells when compared with 
untreated cultures and cultures transduced with scramble shRNA lentivirus 
particles (Figure 3.5A and C).  
Terminal differentiation (CD233/CD49d) was additionally determined using 
flow cytometry in four independent cultures (n=4) (Figure 3.5B and C). There 
was a reduction in the % of (CD233+/CD49d+) cells in cultures transduced with 
PGC-1α shRNA lentivirus particles compared with scramble shRNA and 
untreated cultures indicating that PGC-1α might have a role in terminal 







Figure 3.5. The effects of PGC-1α knockdown on differentiation 
(CD235a/CD71) and terminal differentiation (CD233/CD49d) in primary 
human CD34+ derived erythroid cell culture. 
A) Flow cytometry profiles of a representative experiment for untreated cultures, 
cultures transduced with scramble shRNA lentivirus particles, and cultures 





labeled CD235a antibodies and PE-labeled CD71 antibodies on Day 13. B) Flow 
cytometry profiles of a representative experiment for untreated cultures, cultures 
transduced with scramble shRNA lentivirus particles, and cultures transduced 
with PGC-1α shRNA lentivirus particles were stained with APC-labeled CD233 
antibodies and BV421-labeled CD49d antibodies on Day 13. C) This graph 
summarizes the results for % of CD235a+/CD71+ and CD233+/CD49d+ cells from 
four independent experiments (n = 4). There was no significant difference in % of 
CD235a+/CD71+ in cultures transduced with PGC-1α knockdown (96.2 ± 1.7%) 
compared to cultures transduced with scramble shRNA (97.8 ± 1.1%) and 
untreated cultures (98.3 ± 0.9%). However, the % of CD233+/CD49d+ cells in 
cultures transduced with PGC-1α knockdown was significantly reduced (56.5 ± 
8%) compared to untreated cultures (82.3 ± 5.5%) and culture transduced with 
scramble shRNA (81.1 ± 6.9%). There was no significant difference between 
scramble shRNA treated and untreated cultures. NS; not statistically significant. 












3.3.6 PGC-1α knockdown had no impact on the expression of major 
transcription factors involved in HbF expression in primary human CD34+ 
derived erythroid cells 
The mRNA expression for the major transcription factors in HbF regulation 
was examined (Figure 3.6). There was no statistically significant difference in 
LSD1, BCL11A, KLF1, SIRT1, MYB, and ZBTB7A mRNA expression in cultures 
transduced with PGC-1α shRNA lentivirus particles compared with cultures 
transduced with scramble shRNA lentivirus particles.  
 
 
Figure 3.6. The effects of PGC-1α knockdown on hemoglobin transcription 
factors mRNA expression in primary human CD34+ derived erythroid cell.  
RT-qPCR results for the mRNA expression of 6 major transcription factors in HbF 
regulation in untreated cultures, cultures transduced with scramble shRNA 
lentivirus particles, and cultures transduced with PGC-1α shRNA lentivirus 





SIRT1, MYB, and ZBTB7A mRNA expression with PGC-1α knockdown (1.1 ± 
0.1-fold, 1 ± 0.1-fold, 0.8 ± 0.3-fold, 1.1 ± 0.6-fold, 1.1 ± 0.6-fold, and 2.1 ± 0.7-
fold, respectively) compared with cultures transduced with scramble shRNA 
lentivirus particles. However, there was a statistically significant but slight 
increase in LSD1 expression in cells transduced with scramble shRNA and PGC-
1α shRNA lentivirus (1.3 ± 0.2-fold and 1.1 ± 0.1, respectively) when compared 
with untreated cells. Note also an increase in ZBTB7A expression in scramble 
shRNA transduced cells (1.6 ± 0.3-fold) compared to untreated cells. NS; not 
statistically significant. P-values; * = 0.02, ** = 0.001. 
 
3.4 DISCUSSION 
PGC-1α is a co-activator that regulates gene expression by interacting 
with and binding to transcription factors (178). It also has a role in RNA 
metabolism(188). Studies have suggested that it can bind to RNA polymerase II, 
and thus modulate transcription (178,188). Cui et al., (2015) reported that PGC-1α 
also can enhance γ-globin gene expression in transgenic mouse bone marrow 
progenitor cells derived erythroid cell cultures in vitro(10). Nevertheless, the 
possible role of PGC-1α in human erythropoiesis and hemoglobin regulation 
remains unclear. 
In the present study, a 3-phase primary human CD34+ cell derived 
erythroid cell culture was used to investigate the effect of PGC-1α 





PGC-1α insert and puromycin resistance was transduced to the cultured cells in 
vitro. Puromycin resistance was used to select for transduced cells. In these 
transduced erythroid cells, PGC-1α expression was markedly increased. 
 In these experiments, erythroid cells with PGC-1α overexpression, 
displayed a highly significant upregulation of γ-globin mRNA expression and 
increased F-cell expression as determined by flow cytometry after staining with 
anti-human γ-globin chain antibodies. These findings corroborate with published 
literature, confirming that PGC-1α plays a significant role in regulating γ-globin 
gene expression.  
Only 30-40% of cultured erythroid cells were F-cells, cells containing HbF 
detectable by staining with anti-γ-globin chain antibodies, even though probably 
all the cultured cells had been transduced with the lentiviral vector containing the 
PGC-1α insert as shown by their puromycin resistance. Multiple factors could 
account for the heterogeneous distribution of HbF in these cultured cells; 1) It is 
possible that each progenitor cell was transduced with varying numbers of 
lentiviral particles, and only those with high lentiviral copy number integration into 
their genome were capable of producing sufficient γ-globin chains to be 
detectable by flow cytometry. Potentially, this can be tested for by single-cell 
DNA analysis. 2) Varying sites of lentiviral genomic integration might modulate 
and result in varying PGC-1α expression. 3) Lastly and importantly, it has been 





To address the issue of the mechanism whereby PGC-1α upregulates γ-
globin gene expression, we first examined the differentiation dynamics of 
erythroid cell in culture by interrogating the expression of relevant cell surface 
membrane antigens, CD235a (glycophorin A, a marker of erythroid cell), CD71 
(transferrin receptor 1), CD233 (band 3 anion transport protein), and CD49d 
(Integrin alpha 4, a marker for erythroid precursor only). These results indicate 
that overexpression of PGC-1α does not have a demonstrable effect upon the 
erythroid cell differentiation dynamics.  
There are transcription factors which can act as silencers or enhancers for 
γ-globin gene expression in adults. The mRNA levels of 6 major transcription 
factors (LSD1, BCL11A, KLF1, SIRT1, MYB, and ZBTB7A) were determined in 
cultured erythroid cells. Overexpression of PGC-1α leads to ~50% decrease in 
BCL11A and ZBTB7A mRNA. These two transcription factors are known 
silencers of γ-globin gene expression in adults(4,124). Thus, the effect on the γ-
globin gene expression by PGC-1α upregulation might be completely or partially 
mediated through these two transcription factors. However, while mRNA levels 
often equate to protein levels, there are exceptions. In the future, the amounts of 
BCL11A and ZBTB7A protein levels after PGC-1α overexpression will need to be 
determined. 
Overexpression of PGC-1α also leads to a significant increase of MYB 
mRNA. MYB affects cellular proliferation and differentiation in erythroid and many 





alter the differentiation dynamics of these erythroid cultures. MYB is also known 
to affect γ-globin gene expression – downregulation of MYB is associated with 
increased γ-globin gene expression and the reverse with upregulation of 
MYB(211). Future experiments will need to examine MYB protein level and 
possible post-transcriptional modifications to determine the functional correlation 
between PGC-1α and MYB upon γ-globin gene expression. 
To knockdown PGC-1α, shRNA lentivirus particles were transduced into 
primary human CD34+ derived erythroid cell cultures. In these experiments, 
PGC-1α level was decreased to ~50% of normal. But no demonstrable effect was 
observed on HbF mRNA expression and F-cell production. Cellular differentiation 
pattern and levels of 6 major transcription factor mRNA were not distinctly 
altered, apart from reduction in % of CD233+/CD49d+ cells but further 
experiments are needed to investigate this observation. Whether or not even 
more downregulation of PGC-1α might lead to changes in HbF and F-cell 
expression awaits future experiments.  
In summary, these experiments support the hypothesis that increased 
PGC-1α in primary human cultured erythroid cells can lead to significantly 
increased γ-globin gene expression and F-cell production. Furthermore, these 
experiments establish that primary human CD34+ derived erythroid cell culture is 
a useful experimental platform for the exploration of the effect of PGC-1α 
agonists and other candidate small molecules upon γ-globin gene expression 






CHAPTER IV: Effect of ZLN005, a PGC-1α agonist on F-cell expression in 
primary human CD34+ derived erythroid cells in vitro 
4.1 INTRODUCTION OF PGC-1α AGONISTS 
In pursuit of inducing F-cells as a means of reducing the clinical severity of 
sickle cell anemia through modulating PGC-1α activity, a number of PGC-1α 
agonists were investigated.  
PGC-1α can be activated by either 1) Increasing the amount of PGC-1α 
protein; 2) Post-translational modification of PGC-1α; or 3) Both(178,181,212,213). 
Several pathways can activate PGC-1α, including: 1) Peroxisome proliferator 
activated receptor γ (PPARγ)(212) , 2) Adenosine monophosphate activated 
protein kinase (AMPK)(212), 3) Silent mating type information regulation 2 
homolog1 (SIRT1) pathways (212,213), 4) Mitogen activated protein kinase 
(MAPK)(181). These pathways increase PGC-1α activity by either increasing 
mRNA expression (via PPARγ, AMPK) or through post-translation modifications 
(via AMPK, SIRT1, MAPK)(181,196,212) (Figure 4.1), and they can be 
pharmaceutically targeted to activate PGC-1α(212). The PPARγ pathway can be 
activated, for example by bezafibrate or rosiglitazone, AMPK pathway can be 
activated by metformin, AICAR or ZLN005 and the SIRT1 pathway can be 
activated by resveratrol(11,212,213). It should be noted that activation of PGC-1α by 
post-translational modification can lead to an increase of PGC-1α mRNA 






Figure 4.1. Murine PGC-1α sites of post-translational modifications.  
The activation domain, spanning from aa 1 to aa 180, serves as a binding 
surface for transcription factors and histone-modifying proteins. The repression 
domain, spanning from aa 181 to aa 403, contains a binding site for myb-binding 
protein (MYBBP1A), which represses PGC-1α activity. The C-terminal of PGC-1α 
contains an arginine/serine-rich region (RS) and an RNA recognition motif 
(RRM), which are important for mRNA processing. Multiple regions of PGC-1α 
are subjected to post-translational modifications that alter its activity, binding, and 
localization. AMPK phosphorylate murine PGC-1α at amino acid position T177 
and S538. SIRT1 deacetylate PGC-1α but the exact location is not yet known(214). 
P38 MAPK phosphorylate murine PGC-1α at amino acid T262, T265 and T298 






Wang et al., (2014)(215) reviewed and described more than 15 natural 
compounds and over 30 naturally occurring plant sources that activate 
PPARγ(215). However, activation of the PPARγ pathway could lead to deleterious 
dysregulation of erythroid progenitor cell proliferation and differentiation(216-219). 
Therefore, these compounds were not pursued further in the present study. 
Rasbach and Schnellmann (2008)(214) reviewed 9 compounds that activate PGC-
1α through SIRT1(214). SIRT1 was recently reported to up-regulate γ-globin gene 
expression(131). It is not known if γ-globin gene up-regulation by SIRT1 is 
facilitated through PGC-1α. Ultimately, the search for agonists of PGC-1α 
mediated through the AMPK pathway took priority. Metformin induces PGC-1α 
expression in rat skeletal muscle(220), and rat hippocampi(221) in vivo, while AICAR 
induces PGC-1α expression in rat skeletal muscles in vivo(222). ZLN005 induces 
PGC-1α expression in rat L6 myotubes cell cultures(11), and in the brain of rats in 
vivo(223). We screened metformin, AICAR and ZLN005 to determine whether they 
would induce PGC-1α in primary human CD34+ derived erythroid cells in vitro. 
We found that AICAR and ZLN005 induced PGC-1α mRNA expression. We then 
screened using flow cytometry whether AICAR and ZLN005 increased F-cells in 
primary human CD34+ derived erythroid cells. We found in our screen that 
ZLN005 appeared to be more potent in the induction of F-cells than AICAR (Data 
not shown). Therefore, the focus of my work was on ZLN005.  
SR-18292 is an analog of ZLN005 (Figure 4.2). SR-18292 promotes 





acetylation is yet to be determined(12). Sharabi et al., (2017), also described other 
potential PGC-1α acetylation compounds. C-18 has an AC50 of 1.5 µM toward 
PGC-1α acetylation, and therefore more potent than SR-18292(12). However, SR-
18292 is commercially available.  
 
Figure 4.2. Chemical structure of ZLN005 and SR-18292.  
A) The structure of ZLN005 indicates that it is an organic compound which is 
hydrophobic. It has a tert-butyl group, phenylene, and benzimidazole ring. The 
solubility is 0.25mg/ml in 1:3 solution of DMSO: PBS. That is extremely low, and 
it is almost impossible to dissolve this compound in PBS alone. B) The structure 
of SR-18292 shows that it is also an organic compound that is hydrophobic. 
Similar to ZLN005, SR-18292 has a tert-butyl group and phenylene ring, and it 
has an indole ring. The solubility is 0.33mg/ml in 1:2 solution of DMSO: PBS. The 
solubility of this compound in aqueous solution is better than ZLN005 due to the 
presence of OH group. (Adapted and redrawn from Zhang et al., (2013)(11) and 






 Another potential compound is GSK4716, an estrogen-related receptor-γ 
(EERγ) agonist, that has the ability to activate PGC-1α (224). However, due to time 
constraints, it was not included in my work. 
Another potential pathway that was not pursued was the p38 MAPK-
dependent phosphorylation of PGC-1α that leads to the dissociation of PGC-1α 
from the negative regulator p160 myb-binding protein (MYBBP1A)(181,214,225) 
(Figure 4.1). MTBT (2-3-methyl-thiophen-2-yl-4-3,4-dioxybenzene-thiazole) 
activates the p38 MAPK pathway via phosphorylation(226). Modulating MAPK 
pathway can lead to the arrest of cell mitotic division(226), which might affect 
erythrocyte differentiation and proliferation. Additionally, MTBT is not readily 
available, and as such, this compound was not pursued further.  
 
4.2 HYPOTHESIS 
In Chapter 3, it was demonstrated that up-regulation of PGC-1α leads to 
increased F-cells production in primary human CD34+ derived erythroid cells in 
vitro. Since ZLN005 is a PGC-1α agonist, my hypothesis is that ZLN005 can 









1- To assess the effectiveness of ZLN005 on the induction of PGC-1α and 
F-cells in primary human CD34+ derived erythroid cells in vitro. 
2- To determine the effect of ZLN005 on primary human CD34+ derived 
erythroid cells in vitro upon: a) Erythroid cell differentiation dynamics and b) The 
level of known major transcription factors capable of regulating HbF expression.  
3- To determine if ZLN005, in combination with hydroxyurea, will have a 
synergic effect on F-cell induction in primary human CD34+ derived erythroid 
cells in vitro.  
 
4.4 RESULTS 
4.4.1 ZLN005 in primary human CD34+ derived erythroid cell culture led to 
elevated F-cell expression 
Primary human CD34+ derived erythroid cells were cultured in a three-
phase culture system. In phase 1, the erythroid cells were treated with 25 µM 
hydroxyurea (positive control), 1, 5 and 10 µM ZLN005 on Day 4, and harvested 
on day 13 (phase 3), as described in Chapter II, Section 2.1.  
Figure 4.3A and B shows the assays for cellular viability using Zombie 
dye. There was no difference between cultures treated with 25 µM hydroxyurea 
(87.2 ± 5.7%), 1 and 5 µM ZLN005 (95.6 ± 2.2% and 89.5 ± 3.4%, respectively) 
when compared to vehicle control (97.1 ± 2.5%). There is a statistically 





compared to vehicle control. Figure 4.3C shows that PGC-1α mRNA was 
significantly increased in cultures treated with 1 µM ZLN005 (4.1 ± 1.2-fold) 
compared to vehicle control cultures. There was an increase in PGC-1α mRNA 
expression in cultures treated with 5 µM ZLN005 (2.6 ± 1.1-fold) but that increase 
was not statistically significant (p=0.06) when compared to the vehicle control. 
Additionally, there was no significant difference in PGC-1α mRNA expression 
between cultures treated with 1 µM and 5 µM ZLN005. Due to the reduction in % 
of live cells, RT-qPCR for 10 µM ZLN005 treated cultures was not carried out. 
Importantly, cultures treated with 1 and 5 µM ZLN005 had a significant increase 
in % of F-cells (30.3 ± 3.4% and 26 ± 7% F-cells, respectively) compared to 
vehicle control 7.3 ± 3.4% and untreated 10.4 ± 1%. Cultures treated with 25 µM 






Figure 4.3. Cell viability, PGC-1α mRNA and F-cells expression in primary 
human CD34+ derived erythroid cell culture treated with ZLN005.  
A) Flow cytometry profile of a representative experiment using Zombie dye for 
cell viability assay. B) Summary of viability dye flow cytometry data from 3 
different individuals (n=3). There was no significant statistically difference in live 
cell % in cultures treated with either 1 or 5 µM ZLN005 or 25 µM hydroxyurea 
when compared to the vehicle control. Cultures treated with 10 µM ZLN005 had 





(97.1 ± 2.5%). C) PGC-1α mRNA levels as determined by RT-qPCR in untreated 
cultures, cultures treated vehicle control, 25 µM hydroxyurea, 1 µM ZLN005 and 
5 µM ZLN005 (n=3). The PGC-1α mRNA levels found in cultures treated with 1 
µM ZLN005 is increased to 4.1 ± 1.2-fold of that found in the vehicle control 
cultures. There was no statistically significant increase in PGC-1α mRNA 
expression in cultures treated with either 25 µM hydroxyurea (1.2 ± 0.7-fold) or 5 
µM ZLN005 (2.6 ± 1.1-fold) compared to the vehicle control cultures, and there 
was no statistically significant difference in PGC-1α mRNA expression between 
cultures treated with 1 and 5 µM ZLN005. D) Flow cytometry profiles of a 
representative experiment showing F-cells % in three control cultures, untreated 
culture, culture treated with the vehicle control, and culture treated with 25 µM 
hydroxyurea (positive control), and cultures treated with 1 and 5 µM ZLN005. 
Cells were gated on CD235a, a marker for erythroid cells. The culture treated 
with 1 and 5 µM ZLN005 had 26.3% and 17.5% F-cells, respectively, compared 
to 32.2% in 25 µM hydroxyurea treated culture and 9.2% and 2.7% in untreated 
and vehicle treated cultures, respectively. E) Summary of flow cytometry data of 
F-cell % generated from cultures with CD34+ cells from 3 different individuals 
(n=3). Those cultures treated with 1 and 5 µM ZLN005 had 30.3 ± 3.4% and 26 ± 
7% F-cells, significantly higher than the vehicle control 7.3 ± 3.4% and untreated 
10.4 ± 1%. 25 µM hydroxyurea, used as a positive control, shows 36.9 ± 11 %, 
significant increase F-cells compared to the vehicle control. There was no 





1, 5 µM ZLN005 and 25 µM hydroxyurea. NS; not statistically significant. (Un); 
untreated. (VC); vehicle control. (HU); 25 µM hydroxyurea. (Z1); ZLN005 1 µM. 
(Z5); ZLN005 5 µM. (Z10); ZLN005 10 µM. P values; * = 0.02; ** = 0.01; *** = 
0.001 
 
Unexpectedly, there was no statistically significant differences in γ- and β-
globin mRNA expressions when measured by RT-qPCR on day 13 of cultures 
treated with 25 µM hydroxyurea and cultures treated with 1 and 5 µM ZLN005 
(Figure 4.4). A detailed time course study should yield an increase in γ-globin 
mRNA expression likely at earlier days in these cultures. Interestingly, there 
might be post-transcriptional regulation of γ-globin expression, and that 
transcription of γ-globin genes might not always equate to and accompany by 
efficient HbF expression(227). 
Figure 4.4. γ- and β-globin mRNA expression after ZLN005 treatment in 
primary human CD34+ derived erythroid cell culture. 
The expression of γ- and β-globin mRNA was determined using RT-qPCR on day 





with 25 µM hydroxyurea and cultures treated with 1 and 5 µM ZLN005. In three 
different experiments (n=3), there was no statistically significant difference in γ-
globin mRNA expression in 25 µM hydroxyurea (1.1 ± 0.2-fold), 1 µM ZLN005 
(0.9 ± 0.2-fold) and 5 µM ZLN005 (0.7 ± 0.3-fold) and no statistically significant 
difference in β-globin mRNA expression in 25 µM hydroxyurea (1.2 ± 0.3-fold), 1 
µM ZLN005 (1.1 ± 0.06-fold) and 5 µM ZLN005 (1.1 ± 0.2-fold) when compared 
to vehicle control. NS; not statistically significant. (Un); untreated. (VC); vehicle 
control. (HU); 25 µM hydroxyurea. (Z1); ZLN005 1 µM. (Z5); ZLN005 5 µM.  
 
To ascertain the sensitivity of RT-qPCR assay for γ-globin mRNA 
determination in erythroid cell cultures, the following experiments were carried 
out on undifferentiated HUDEP-1 cells. These are immortalized human umbilical 
cord blood-derived erythroid progenitors(200). With erythroid cell differentiation 
induction protocol(200,228), HUDEP-1 cells give arise to erythroid cells expressing 
primarily γ-globin(200). However, in the following experiments, HUDEP-1 cells 
were not induced to undergo erythroid cell differentiation, and these cells 
produce minimal amount of γ-globin(200).  
HUDEP-1 cell cultures were treated with 100 µM hydroxyurea and 2.5, 5 
and 7.5 µM ZLN005 (Figure 4.5). There was a statistically significant increase (4 
± 1.6-fold) in γ-globin mRNA level in cultures treated with 100 µM hydroxyurea 





found in cultures treated with 2.5, 5 and 7.5 µM ZLN005 is significantly increased 
to 2.2 ± 0.4-fold, 2.6 ± 0.1-fold, and 3.8 ± 1.4-fold, respectively, of that found in 
the vehicle control cultures (Fig. 4.5 B). These results demonstrated the 
robustness of the RT-qPCR assay for γ-globin mRNA determination in erythroid 
cell cultures.  
 
 
Figure 4.5. PGC-1α mRNA, γ-globin mRNA and F-cells expression in 
HUDEP-1 cell line culture.  
A) PGC-1α mRNA levels as determined by RT-qPCR in untreated cultures, 
cultures treated vehicle control, 100 µM hydroxyurea, 2.5, 5 and 7.5 µM ZLN005 
(n=3). The PGC-1α mRNA levels found in cultures treated with 2.5 and 5 µM 





respectively, of that found in vehicle control cultures. There was no statistically 
significant increase in PGC-1α mRNA expression in cultures treated with 100 µM 
hydroxyurea and 7.5 µM compared to vehicle control. There was no statistically 
significant difference between cultures treated with 2.5 and 5 µM ZLN005. B) γ-
globin mRNA levels as determined by RT-qPCR in untreated cultures, cultures 
treated vehicle control, 100 µM hydroxyurea, 2.5, 5 and 7.5 µM ZLN005 (n=3). 
The γ-globin mRNA levels found in cultures treated with 2.5, 5 and 7.5 µM 
ZLN005 is significantly increased to 2.2 ± 0.4-fold, 2.6 ± 0.1-fold, and 3.8 ± 1.4-
fold, respectively, of that found in vehicle control cultures. Γ-globin mRNA levels 
found in cultures treated with 100 µM hydroxyurea (positive control) is 
significantly increased (4 ± 1.6-fold) compared to vehicle control. C) Flow 
cytometry profiles of a representative experiment showing F-cells % in three 
control cultures, untreated culture, culture treated with vehicle control, and 
culture treated with 100 µM hydroxyurea (positive control), and cultures treated 
with 2.5, 5 and 7.5 µM ZLN005. The culture treated with 2.5, 5 and 7.5 µM 
ZLN005 had 72.4%, 81.3% and 60.8% F-cells, respectively, compared to 94.2% 
in 100 µM hydroxyurea treated culture and 32.7% and 27.1% in untreated and 
vehicle treated cultures, respectively. E) Summary of flow cytometry data of F-
cell % generated from cultures with CD34+ cells from 3 different individuals (n=3). 
Those cultures treated with 2.5, 5 and 7.5 µM ZLN005 had 63.6 ± 9.3, 66.7 ± 
14.5% and 56.5 ± 8.6% F-cells, significantly higher than vehicle control 29.5 ± 





control, produced a significant increase in F-cells (84.6 ± 6%) compared to 
vehicle control. There was no statistically significant difference when cultures 
treated with either 2.5, 5 or 7.5 µM ZLN005 were compared with cultures treated 
with 100 µM hydroxyurea. NS; not statistically significant. (Un); untreated. (VC); 
vehicle control. (HU); 100 µM hydroxyurea. (Z2.5); ZLN005 2.5 µM. (Z5); ZLN005 
5 µM. (Z7.5); ZLN005 7.5 µM. P values; *<0.05; **<0.005; ***<0.0005; 
****<0.00005. 
 
4.4.2 The effect of ZLN005 on the differentiation kinetics in primary human 
CD34+ derived erythroid cell culture 
Erythroid cellular differentiation markers (CD235a/CD71) and terminal 
differentiation markers (CD233/CD49d)(207) were determined using flow cytometry 
in cells obtained from cultures treated with 25 µM hydroxyurea, 1, and 5 µM 
ZLN005. There was no statistically significant difference in CD235a+/CD71+ 
among all cultures. Additionally, ZLN005 at 1 and 5 µM did not have any 
demonstrable effect on (CD233/CD49d), while 25 µM hydroxyurea significantly 
increase the % of CD233+/CD49d+ (72.6 ± 10.4%) compared to the vehicle 







Figure 4.6. The effects of ZLN005 on differentiation (CD235a/CD71) and 
terminal differentiation (CD233/CD49d) in primary human CD34+ derived 
erythroid cell culture.  
A) Flow cytometry profiles of a representative experiment for three control 
cultures, untreated cultures, cultures treated with vehicle control and the other 
with 25 µM hydroxyurea (positive control), and cultures treated with 1 and 5 µM 
ZLN005 all stained with APC-labeled CD235a antibodies and BV421-labeled 
CD71 antibodies. B) Flow cytometry profiles of a representative experiment for 
the same cultures in panel A but stained with APC-labeled CD233 antibodies and 





CD235a+/CD71+ cells and % of CD233+/CD49d+ cells from three independent 
experiments (n = 3). There was no statistically significant difference in % of 
CD235a+/CD71+ cells between untreated cultures (90.8 ± 5.6%), cultures treated 
with the vehicle control (89 ± 7.6%), 25 µM hydroxyurea treated cultures (89.6 ± 
9%), 1 and 5 µM ZLN005 treated cultures (91 ± 4.7% and 92 ± 4%, respectively). 
Additionally, there was no statistically significant difference in % of 
CD233+/CD49d+ cells between untreated cultures (46.4 ± 6.6%), cultures treated 
with the vehicle control (47.9 ± 7.2%), 1 and 5 µM ZLN005 treated cultures (47.6 
± 2.5% and 53.5 ± 7.5%, respectively). However, there is a statistically significant 
increase in % of CD233+/CD49d+ cells in cultures treated with 25 µM 
hydroxyurea (72.6 ± 10.4%) compared to the vehicle control (47.9 ± 7.2%). NS; 
not statistically significant. (Un); untreated. (VC); vehicle control. (HU); 25 µM 
hydroxyurea. (Z1); ZLN005 1 µM. (Z5); ZLN005 5 µM. P values; * = 0.05. 
 
4.4.3 The effect of ZLN005 on transcriptional factors known to regulate HbF 
expression in primary human CD34+ derived erythroid cell culture 
The mRNA expression for 6 major transcription factors in HbF regulation 
was examined (Figure 4.7). There was no statistically significant difference in 
LSD1, BCL11A, KLF1, SIRT1, MYB, and ZBTB7A mRNA expression in 
untreated cultures, vehicle treated cultures, cultures treated with 25 µM 







Figure 4.7. The effects of ZLN005 on hemoglobin transcription factors 
mRNA expression in primary human CD34+ derived erythroid cell.  
RT-qPCR results for the mRNA expression of 6 major transcription factors in HbF 
regulation in untreated cultures, vehicle treated cultures, cultures treated with 25 
µM hydroxyurea, and cultures treated with 1 and 5 µM ZLN005 (n=3). There was 
no statistically significant difference in LSD1, BCL11A, KLF1, SIRT1, MYB, and 
ZBTB7A mRNA expression with 1 µM ZLN005 (1.7 ± 1.2-fold, 1.4 ± 0.4-fold, 1.2 
± 0.4-fold, 1.2 ± 0.3-fold, 1.5 ± 0.4-fold, and 1.3 ± 0.4-fold, respectively) and 5 µM 
ZLN005 (1.7 ± 0.8-fold, 1.4 ± 0.2-fold, 1.3 ± 0.6-fold, 1.5 ± 0.7-fold, 1.1 ± 0.3-fold, 
and 1.6 ± 0.6-fold, respectively) treated cultures when compared to the vehicle 
control. NS; not statistically significant. (Un); untreated. (VC); vehicle control. 





4.4.4 ZLN005 in combination with hydroxyurea has a synergistic effect on 
F-cell numbers in primary human CD34+ derived erythroid cell culture 
Figure 4.8A and B show the viability assaying using Zombie dye. There 
was no statistically significant difference among cultures treated with 25 µM 
hydroxyurea, 1, 5 µM ZLN005 and the combination of 25 µM hydroxyurea with 
either 1 or 5 µM ZLN005 when compared to vehicle control.  
Figure 4.8C and D show a synergistic effect on F-cells expression; the 
combination of 1 µM ZLN005 and 25 µM hydroxyurea shows a marked increase 
in F-cells (50.4 ± 3.8%) when compared to 25 µM hydroxyurea alone (30.4 ± 9%) 
or 1 µM ZLN005 alone (26 ± 6.5%). Similarly, 5 µM ZLN005 and 25 µM 
hydroxyurea combination shows a synergistic effect (51.9 ± 9.9%) when 















Figure 4.8. Viability and F-cells expression with ZLN005 in combination 
with hydroxyurea in primary human CD34+ derived erythroid cell. 
A) Flow cytometry profile of a representative experiment using Zombie dye for 
cell viability assay. B) Summary of viability dye flow cytometry data from 3 
different individuals (n=3). There was no statistically significant difference in live 
cell % in cultures treated with 25 µM hydroxyurea (91.7 ± 7.5%), 1 µM ZLN005 
(94.5 ± 3%), 1 µM ZLN005 in combination with 25 µM hydroxyurea (95 ± 2.4 %), 
5 µM ZLN005 (88 ± 9%) and 5 µM ZLN005 in combination with 25 µM 
hydroxyurea (94.9 ± 2.2%) when compared to cultures treated with the vehicle 
control (96 ± 2.5%) and untreated cultures (96 ± 2%). C) Flow cytometry profiles 
of a representative experiment showing F-cells % in three control cultures, 
untreated culture, culture treated with vehicle control, and culture treated with 25 





with and without 25 µM hydroxyurea combination. Cells were gated on CD235a, 
a marker for erythroid cells. D) Summary of flow cytometry data of F-cell % 
generated from cultures with CD34+ cells from 3 different individuals (n=3). In 
cultures treated with 1 µM ZLN005 combined with 25 µM hydroxyurea had a 
significantly higher F-cells (50.4 ± 3.8%) when compared to 25 µM hydroxyurea 
(30.4 ± 9%) and compared to 1 µM ZLN005 (26 ± 6.5%). Similarly, 5 µM ZLN005 
and 25 µM hydroxyurea combination shows a synergistic effect (51.9 ± 9.9%) 
when compared to 25 µM hydroxyurea and compared to 5 µM ZLN005 (19.7 ± 
1%). NS; not statistically significant. (Un); untreated. (VC); vehicle control. (HU); 
25 µM hydroxyurea. (Z1); ZLN005 1 µM. (Z5); ZLN005 5 µM. P values; * = 0.04; 
** = 0.02; *** = 0.005. 
 
4.4.5 The effect of ZLN005 combined with hydroxyurea treatment on the 
differentiation kinetics in primary human CD34+ derived erythroid cell 
culture 
 Figure 4.9 shows that combining either 1 µM or 5 µM ZLN005 with 25 µM 
hydroxyurea had no demonstrable effect on the differentiation dynamics as 
determined by CD235a/CD71 and CD233/CD49d expression in primary human 







Figure 4.9. The effects of ZLN005 combined with hydroxyurea on 
differentiation (CD235a/CD71) and terminal differentiation (CD233/CD49d) in 
primary human CD34+ derived erythroid cell culture.  
A) Flow cytometry profiles of a representative experiment for three control 
cultures, untreated cultures, cultures treated with vehicle control and the other 
with 25 µM hydroxyurea (positive control), and cultures treated with 1, 5 µM 
ZLN005 with and without 25 µM hydroxyurea combination, all stained with APC-
labeled CD235a antibodies and BV421-labeled CD71 antibodies. B) Flow 
cytometry profiles of a representative experiment for the same cultures in panel A 
but stained with APC-labeled CD233 antibodies and BV421-labeled CD49d 





CD233+/CD49d+ cells from three independent experiments (n=3). There was no 
statistically significant difference in % of CD235a+/CD71+ cells between untreated 
cultures (96.2 ± 0.2%), vehicle control cultures (98.5 ± 0.8%), 25 µM hydroxyurea 
treated cultures (96.7 ± 0.8), 1 and 5 µM ZLN005 treated cultures without 25 µM 
hydroxyurea (95.2 ± 1.2% and 86.9 ± 3.3%, respectively) and with 25 µM 
hydroxyurea combination (93 ± 1.2 % and 93.5 ± 2.5%, respectively). 
Additionally, there was no statistically significant difference in % of 
CD233+/CD49d+ cells between untreated cultures (47.7 ± 10.9%), cultures 
treated with the vehicle control (55.9 ± 7.5%), 1 and 5 µM ZLN005 treated 
cultures without hydroxyurea (58.6 ± 4.4% and 53 ± 8.3%, respectively) or in 
combination with 25 µM hydroxyurea (54.9 ± 6.8% and 58.4 ± 6.4%, 
respectively). However, there is a statistically significant increase in % of 
CD233+/CD49d+ cells in cultures treated with 25 µM hydroxyurea (72.6 ± 3.8%) 
compared to vehicle control. NS; not statistically significant. (Un); untreated. 
(VC); vehicle control. (HU); 25 µM hydroxyurea. (Z1); ZLN005 1 µM. (Z5); 











In Chapter III, I reported that PGC-1α overexpression can induce γ-globin 
gene expression and F-cell production in primary human CD34+ derived from 
erythroid cell culture. ZLN005 is a known PGC-1α agonist(11,223), and it is used for 
in vivo and in vitro PGC-1α research. ZLN005 at 1 µM can up-regulate PGC-1α 
mRNA expression to 4-fold that of controls in these primary human erythroid cell 
cultures (Figure 4.3C). ZLN005 can activate PGC-1α through the AMPK 
pathway(11), which ultimately leads to phosphorylation of human PGC-1α(196) at 
amino acid positions T178 and S539(229). PGC-1α activation can also promote an 
increase in its mRNA synthesis(11,193). Both mechanisms (increased PGC-1α 
expression and PGC-1α phosphorylation) probably account for ZLN005 induction 
of PGC-1α mRNA expression.  
I proposed to test the hypothesis that ZLN005 can increase F-cell 
production in primary human CD34+ derived erythroid cell culture. The first set of 
experiments were done to establish that ZLN005 at 1 or 5 µM had no significant 
effect on cell viability. But at 10 µM, cell viability was clearly compromised 
(Figure 4.3A and B). ZLN005 at 1 and 5 µM significantly increase F-cell % in 
primary human CD34+ progenitor cells derived from erythroid cell culture 
compared to control cultures. The F-cell % increase at ~30% was comparable to 
cultures treated with 25 µM hydroxyurea (Figure 4.3D and E). Of note is that the 





hydroxyurea is ~25 µM during most of the day(230), identical to the hydroxyurea 
concentration used in our culture experiments.  
ZLN005 at 1 and 5 µM did not have a significant effect upon erythroid cell 
differentiation dynamics (Figure 4.6) nor upon mRNA levels of 6 transcription 
factors known to regulate γ-globin gene expression (Figure 4.7). These results 
suggest that ZLN005 increases F-cell expression through mechanisms unrelated 
to perturbation of erythroid cell differentiation nor mediated by transcription 
factors known to regulate γ-globin gene expression.  
In previous experiments, markedly elevated PGC-1α overexpression 
achieved by using ectopic lentiviral vector integration led to an increase in γ-
globin mRNA shown by RT-qPCR carried out on day 13 of cultures (Figure 
3.1D). In cultures treated with ZLN005, unexpectedly, there was no statistically 
significant increase of γ-mRNA expression when measured by RT-qPCR on day 
13 of cultures (Figure 4.4). It is likely that a detailed time course study will yield 
an increase in γ-globin mRNA expression at earlier days in these cultures, and 
these experiments should be done in the future. Alternatively, it is possible that 
ZLN005 causes up-regulation of HbF by enhancing the efficiency of translation 
initiation of γ-globin mRNA or by shortening the time required to complete γ-
globin mRNA translation. Post-transcriptional regulation of γ-globin expression 
has been reported showing that transcription of γ-globin genes might not always 





An example of mRNA-Protein discordance can be found with BCL11A 
mRNA and protein level in erythroid cells, where there is a gradient protein 
expression across fetal, newborn, and adult erythroid cells at all maturation 
stages but unexpectedly there is no demonstrable change in BCL11A mRNA(231). 
Additionally, this difference in protein level across different stages of maturation 
could not be explained by a difference in BCL11A mRNA splicing(231). This 
suggests a post-transcriptional regulation mechanism for BCL11A.  
When primary human CD34+ derived erythroid cell cultures were treated 
with ZLN005, at either 1 or 5 µM, together with 25 µM hydroxyurea, many more 
F-cells were produced, up to ~50% (Figure 4.8). Cultures treated with either 
ZLN005 or hydroxyurea alone produced ~20 to 30% F-cells. This synergistic 
effect shows that both compounds enhance F-cell production by different 
mechanisms of action. Hydroxyurea induction of F-cells is likely to be 
multifactorial, with a significant impact on the dynamic of erythroid 
differentiation(4-7). Hydroxyurea may induce F-cells by epigenetic modification, 
gene transcription, and cell signaling(232). Hydroxyurea induce secretin-
associated and Ras-related protein (SAR1) gene that activate γ-globin through 
the JNK/Jun signaling pathway(233). Additionally, hydroxyurea increase nitric 
oxide levels and cyclic nucleotides such as guanylyl cyclase that may impact 
genes that regulate hemoglobin transcription and translation including 
BCL11A(232). This combination of ZLN005 and hydroxyurea did not have a 





importantly, these observations raise the possibility of combination therapy in the 
future for SCD patients with these and related compounds.  
One deficiency of these investigations is that almost all experiments were 
done by RT-qPCR for determination of mRNA levels, except for F-cell 
determination by flow cytometry using monospecific anti-γ-globin chain 
antibodies and erythroid differentiation profile that was done using immune-flow 
cytometry. As such we were not able to address protein levels and post-
translation modifications. Future experiments will need to include Western 
blotting with high affinity antibodies capable of detecting and semi-quantitating 
innate peptides and peptides with post-translation modifications. Mass 
spectrometry is a technique which can aid this process by identifying minute 
amounts of peptide and detecting post-transcriptional and post-translational 
modifications.   
In summary, these experiments demonstrate that ZLN005 can up-regulate 
PGC-1α in primary human erythroid cell cultures and significantly enhance F-cell 
production. Furthermore, a combination of ZLN005 and hydroxyurea, a 
commonly used drug for SCD, led to a highly significant synergistic effect upon 
F-cell production. These results raise the possibility of combination therapy in the 









CHAPTER V: Effect of SR-18292, a PGC-1α agonist on F-cell expression in 
primary human CD34+ derived erythroid cells in vitro 
5.1 INTRODUCTION  
PGC-1α acetylation controls its ability to recruit the chromatin-remodeling 
complex and initiates gene transcription(234). PGC-1α harbors multiple acetylation 
sites that span the whole of its protein sequence(182,234) (Figure 4.1). There are 
several acetyltransferases, including general control nonderepressible-5 (GCN5) 
and steroid receptor co-activators (SRC-1 and SRC-3)(234), that acetylate PGC-
1α(234). However, there are only two identified deacetylases for PGC-1α, namely 
SIRT1 and HDAC3(182,234). GCN5 acetylates PGC-1α at 13 lysine sites(235). The 
acetylation status of PGC-1α via GCN5 is dependent on the quantities of nuclear 
acetyl-CoA(234) which in turn is dependent on the cellular energy balance(12,234). 
Acetylation of PGC-1α can affect its stability, localization, and activity(12,178,182). 
PGC-1α activity and stability are subjected to dynamic and versatile post-
translational modifications in response to cellular stress and other environmental 
signals and consequently, post-translational modifications could account for the 
pleiotropic effect of this co-activator(182,234,235).  
SR-18292 is an analog of ZLN005 (Figure 4.2). SR-18292 has AC50=3.1 
µM(12) and it acetylates lysine residues on PGC-1α at the following sites, K277, 
K346, K359, K371, K373, K479 and K554(12). The first 5 lysine residues are 





PGC-1α activity(182) (Figure 4.1). In addition to SR-18292, there are 8 other 
compounds which can acetylate PGC-1α with AC50 varying from 1.5 – 9.7 µM 
(Figure 5.1). However, these compounds are not readily available for use in our 
experiments.   
 
Figure 5.1. PGC-1α acetylator compounds 
PGC-1α acetylator compounds with their AC50 toward PGC-1α acetylation. The 
mechanism and the location for PGC-1α acetylation is not known. These 
compounds are not available commercially (adopted and redrawn from Sharabi 








In Chapter IV, it was demonstrated that ZLN005, a PGC-1α agonist(11,223) 
can increase F-cells production in primary human CD34+ derived erythroid cells 
in vitro. ZLN005 activates PGC-1α through the AMPK pathway(11), leading to 
phosphorylation of PGC-1α(196) at amino acid residues T178 and S539(229). In this 
chapter, my hypothesis is that SR-18292, a PGC-1α agonist and acetylator, can 




1- To assess the effectiveness of SR-18292 on the induction of PGC-1α 
and F-cells in primary human CD34+ derived erythroid cells in vitro. 
2- To determine the effect of SR-18292 on primary human CD34+ derived 
erythroid cells in vitro upon: a) Erythroid cell differentiation dynamics and b) The 
level of known major transcription factors capable of regulating HbF expression.  
3- To determine if SR-18292, in combination with hydroxyurea, will have a 
synergistic effect on F-cell induction in primary human CD34+ derived erythroid 










5.4.1 SR-18292 induced F-cells expression in primary human CD34+ derived 
erythroid cell culture  
Primary human CD34+ derived erythroid cells were cultured in a three-
phase culture system. Briefly, in phase 1, the erythroid cells were treated with 25 
µM hydroxyurea (positive control) and with 1, 5 and 10 µM SR-18292 on Day 4, 
and harvested on day 13 (phase 3), as described in Chapter II, Section 2.1.  
The assays for cellular viability using Zombie dye are shown in Figure 
5.2A and B. There was no statistically significant difference in live cell % 
between the cultures treated with 25 µM hydroxyurea (89.1 ± 5.8%), 1, 5 and 10 
µM SR-18292 (94.6 ± 3.2%, 94.9 ± 2.4% and 89.6 ± 4.6%, respectively) when 
compared to the vehicle control (96.2 ± 1.7%). Additionally, PGC-1α mRNA was 
significantly increased in cultures treated with 1, 5 and 10 µM SR-18292 (2.6 ± 1-
fold, 2.6 ± 1-fold and 5.7 ± 2.5-fold, respectively) compared to the vehicle control 
cultures with no significant difference in PGC-1α mRNA expression among all 
cultures treated with SR-18292 (Figure 5.2C). Importantly, cultures treated with 
1, 5 and 10 µM SR-18292 had a significant increase in % of F-cells (32 ± 2.9%, 
29.1 ± 6.4% and 26.5 ± 8%, respectively) compared to the vehicle control (8.6 ± 
4.2%) and untreated cultures (9 ± 1.2%). Cultures treated with 25 µM 







Figure 5.2. Cell viability, PGC-1α mRNA and F-cell expression in primary 
human CD34+ derived erythroid cell culture treated with SR-18292.  
A) Flow cytometry profile of a representative experiment using Zombie dye for 
cell viability assay. B) Summary of viability dye flow cytometry data from 3 
different individuals (n=3). There was no statistically significant difference in live 
cell % in cultures treated with either 1, 5 and 10 µM SR-18292 (94.6 ± 3.2%, 94.9 
± 2.4% and 89.6 ± 4.6%, respectively) or 25 µM hydroxyurea (89.1 ± 5.8%) when 
compared to the vehicle control. C) PGC-1α mRNA levels as determined by RT-





1, 5 and 10 µM SR-18292 (n=3). The PGC-1α mRNA levels found in cultures 
treated with 1, 5 and 10 µM SR-18292 is significantly increased to 2.6 ± 1-fold, 
2.6 ± 1-fold and 5.7 ± 2.5-fold, respectively, of that found in the vehicle control 
cultures. There was no significant increase in PGC-1α mRNA expression in 
cultures treated with 25 µM hydroxyurea compared to the vehicle control. There 
was no statistically significant difference among cultures treated with 1, 5 and 10 
µM SR-18292. D) Flow cytometry profiles of a representative experiment 
showing F-cells in three control cultures, untreated culture, culture treated with 
the vehicle control, and a culture treated with 25 µM hydroxyurea (positive 
control), and cultures treated with 1, 5 and 10 µM SR-18292. Cells were gated on 
CD235a, a marker for erythroid cells. The cultures treated with 1, 5 and 10 µM 
SR-18292 had 35.5%, 30.5% and 20.1% F-cells, respectively, compared to 
36.3% in the 25 µM hydroxyurea treated culture and 7.3% and 12.3% in the 
untreated and vehicle treated cultures, respectively. E) Summary of flow 
cytometry data of % F-cells generated from cultures with CD34+ cells from 3 
different individuals (n=3). Those cultures treated with 1, 5 and 10 µM SR-18292 
had 32 ± 2.9%, 29.1 ± 6.4% and 26.5 ± 8% F-cells, respectively, significantly 
higher than the vehicle control 8.6 ± 4.2% and untreated 9 ± 1.2%. 25 µM 
hydroxyurea, used as a positive control, shows 40.2 ± 8.6%, a significant 
increase in F-cells compared to the vehicle control. There was no statistically 
significant difference when comparing cultures treated with either 1, 5 or 10 µM 





significant. (Un); untreated. (VC); vehicle control. (HU); 25 µM hydroxyurea. (S1); 
SR-18292 1 µM. (S5); SR-18292 5 µM. (S10); SR-18292 10 µM. P values; * = 
0.05; ** = 0.03; *** = 0.01; **** = 0.005; ***** = 0.001. 
 
Using RT-qPCR to measure γ- and β-mRNA expression on cells obtained 
on day 13 of culture, there was no statistically significant differences in γ- and β-
globin mRNA expressions on cultures treated with 1, 5 and 10 µM SR-18292 and 
with 25 µM hydroxyurea (Figure 5.3). Identical results were obtained with 
ZLN005 added to these cultures (Figure 4.4). Conceivably a detailed time course 
study may reveal an increase in γ-globin mRNA expression prior to day 13. 
Alternatively, these results may support a post-transcriptional regulation of γ-
globin expression, and that transcription of γ-globin genes might not always 













Figure 5.3. γ- and β-globin mRNA expression after SR-18292 treatment in 
primary human CD34+ derived erythroid cell culture.  
The expression of γ- and β-globin mRNA was determined using RT-qPCR on day 
13 in untreated cultures, cultures treated with the vehicle control, culture treated 
with 25 µM hydroxyurea and cultures treated with 1, 5 and 10 µM SR-18292. In 
three different experiments (n=3), there was no statistically significant difference 
in γ-globin mRNA expression in 25 µM hydroxyurea (1.2 ± 0.3-fold), 1 µM SR-
18292 (0.9 ± 0.4-fold), 5 µM SR-18292 (0.9 ± 0.2-fold) and 10 µM SR-18292 (1 ± 
0.3-fold) and no statistically significant difference in β-globin mRNA expression in 
25 µM hydroxyurea (1.3 ± 0.1-fold), 1 µM SR-18292 (0.8 ± 0.3-fold), 5 µM SR-
18292 (1 ± 0.4-fold) and 10 µM SR-18292 (0.9 ± 0.4-fold) when compared to the 
vehicle control. NS; not statistically significant. (Un); untreated. (VC); vehicle 
control. (HU); 25 µM hydroxyurea. (S1); SR-18292 1 µM. (S5); SR-18292 5 µM. 





5.4.2 The effect of SR-18292 on the differentiation kinetics in primary 
human CD34+ derived erythroid cell culture 
Erythroid cellular differentiation markers (CD235a/CD71) and terminal 
differentiation markers (CD233/CD49d)(207) were determined using flow cytometry 
in cells obtained from cultures treated with 25 µM hydroxyurea and 1, 5 and 10 
µM SR-18292. There was no statistically significant difference in CD235a+/CD71+ 
among all cultures. SR-18292 increased the % CD233+/CD49d+ cells at 1, 5 and 
10 µM (75 ± 6%, 79.7 ± 6% and 84.6 ± 9.8%, respectively). Similarly, 25 µM 
hydroxyurea significantly increased the % CD233+/CD49d+ (75.1 ± 11.7%) 











Figure 5.4. The effects of SR-18292 on differentiation (CD235a/CD71) and 
terminal differentiation (CD233/CD49d) in primary human CD34+ derived 
erythroid cell culture.  
A) Flow cytometry profiles of a representative experiment for three control 
cultures, untreated cultures, cultures treated with the vehicle control, cultures 
treated with 25 µM hydroxyurea (positive control), and cultures treated with 1, 5 
and 10 µM SR-18292 all stained with APC-labeled CD235a antibodies and 
BV421-labeled CD71 antibodies. B) Flow cytometry profiles of a representative 
experiment for the same cultures in panel A but stained with APC-labeled CD233 
antibodies and BV421-labeled CD49d antibodies. C) Summary of the results for 





experiments (n = 3). There was no statistically significant difference in % 
CD235a+/CD71+ cells between untreated cultures (95.3 ± 4.3%), cultures treated 
with the vehicle control (94.4 ± 4.7%), cultures treated with 25 µM hydroxyurea 
(97.1 ± 1.7%), cultures treated with 1, 5 and 10 µM SR-18292 (95.8 ± 2.3%, 96 ± 
3.2% and 90.3 ± 6.8%, respectively). Surprisingly, SR-18292 significantly 
increased the % CD233+/CD49d+ cells at 1, 5 and 10 µM (75 ± 6%, 79.7 ± 6% 
and 84.6 ± 9.8%, respectively) compared to the vehicle control (50.2 ± 5.8%). 
Similarly, 25 µM hydroxyurea significantly increased the % CD233+/CD49d+ 
(75.1 ± 11.7%) compared to the vehicle control. NS; not statistically significant. 
(Un); untreated. (VC); vehicle control. (HU); 25 µM hydroxyurea. (S1); SR-18292 
1 µM. (S5); SR-18292 5 µM. (S10); SR-18292 10 µM. P values; * = 0.05; ** = 
0.02; *** = 0.01. 
 
5.4.3 The effect of SR-18292 on transcriptional factors known to regulate 
HbF expression in primary human CD34+ derived erythroid cell culture 
The mRNA expression for 6 major transcription factors in HbF regulation 
was examined (Figure 5.5). There was no statistically significant difference in 
LSD1, BCL11A, KLF1, SIRT1, MYB, and ZBTB7A mRNA expression in 
untreated cultures, vehicle treated cultures, cultures treated with 25 µM 








Figure 5.5. The effects of SR-18292 on hemoglobin transcription factors 
mRNA expression in primary human CD34+ derived erythroid cell.  
RT-qPCR results for the mRNA expression of 6 major transcription factors in HbF 
regulation in untreated cultures, vehicle treated cultures, cultures treated with 25 
µM hydroxyurea, and cultures treated with 1, 5 and 10 µM SR-18292 (n=3). 
There was no statistically significant difference in LSD1, BCL11A, KLF1, SIRT1, 
MYB, and ZBTB7A mRNA expression with 1 µM SR-18292 (1 ± 0.3-fold, 0.9 ± 
0.6-fold, 2 ± 0.4-fold, 1 ± 0.3-fold, 1.3 ± 0.7-fold, and 1.2 ± 0.4-fold, respectively), 
5 µM SR-18292 (1.2 ± 0.6-fold, 0.9 ± 0.5-fold, 0.9 ± 0.3-fold, 0.9 ± 0.1-fold, 1.6 ± 
0.4-fold, and 0.8 ± 0.4-fold, respectively) and 10 µM SR-18292 (1.9 ± 1.1-fold, 
1.4 ± 0.3-fold, 0.9 ± 0.3-fold, 1 ± 0.3-fold, 2 ± 0.7-fold and 1.3 ± 0.6-fold, 
respectively) treated cultures when compared to the vehicle control. NS; not 
statistically significant. (Un); untreated. (VC); vehicle control. (HU); 25 µM 






5.4.4 SR-18292 in combination with hydroxyurea has a synergistic effect on 
F-cells number in primary human CD34+ derived erythroid cell culture 
Figure 5.6A and B shows that the use of a combination of hydroxyurea 
and SR-18292 had a synergistic effect on % F-cells expression. This combination 
of 1 µM SR-18292 and 25 µM hydroxyurea shows an increase in % F-cells (40.3 
± 4.3%) when compared to 1 µM SR-18292 alone (25.7 ± 7.2%), but not 
statistically significant different from 25 µM hydroxyurea alone. A combination of 
5 µM SR-18292 and 25 µM hydroxyurea shows a marked synergistic effect (60.2 
± 12.6%) when compared to either 25 µM hydroxyurea alone (36.1 ± 7.7%) or to 
5 µM SR-18292 alone (33.6 ± 14.7%). However, a combination of 10 µM SR-
18292 and 25 µM hydroxyurea in these cultures led to a rapid cell death.  
Figure 5.6C and D shows there was no statistically significant difference 













Figure 5.6. F-cells expression and CD235a+/CD71+ with SR-18292 in 
combination with hydroxyurea in primary human CD34+ derived erythroid 
cell. 
A) Flow cytometry profiles of a representative experiment showing F-cells % in 
three control cultures, untreated culture, culture treated with the vehicle control, 
and culture treated with 25 µM hydroxyurea (positive control), and cultures 
treated with 1 and 5 µM SR-18292 with and without 25 µM hydroxyurea. Cells 
were gated on CD235a, a marker for erythroid cells. B) Summary of flow 
cytometry data of F-cell % generated from cultures with CD34+ cells from 4 
different individuals (n=4). Cultures treated with 1 µM SR-18292 combined with 
25 µM hydroxyurea had a significantly higher % F-cells (40.3 ± 4.3%) when 
compared to 1 µM SR-18292 alone (25.7 ± 7.2%). Similarly, a combination of 5 





when compared to either 25 µM hydroxyurea alone (36.1 ± 7.7%) or 5 µM SR-
18292 alone (33.6 ± 14.7%). C) Flow cytometry profiles of a representative 
experiment for three control cultures, untreated cultures, cultures treated with the 
vehicle control, cultures treated with 25 µM hydroxyurea (positive control), and 
cultures treated with 1, 5 µM SR-18292 with and without 25 µM hydroxyurea, all 
stained with APC-labeled CD235a antibodies and BV421-labeled CD71 
antibodies. D) Summary results for % CD235a+/CD71+ cells from four 
independent experiments (n=4). There was no statistically significant difference 
in % CD235a+/CD71+ cells between untreated cultures (98.5 ± 0.3%), vehicle 
control cultures (99.3 ± 0.1%), 25 µM hydroxyurea treated cultures (98.7 ± 0.3), 1 
and 5 µM SR-18292 treated cultures without 25 µM hydroxyurea (99.4 ± 0.3% 
and 97.7 ± 1.6%, respectively) and with cultures treated with a combination of 
SR-18292 and 25 µM hydroxyurea (99 ± 0.1 % and 99.5 ± 0.1%, respectively). 
(Un); untreated. (VC); vehicle control. (HU); 25 µM hydroxyurea. (S1); SR-18292 











In chapter IV, it was shown that ZLN005, a PGC-1α agonist(11) which can 
phosphorylate PGC-1α(196) at amino acid positions T178 and S539(229), led to a 
marked increase in F-cells expression. SR-18292 is a small molecule and an 
analog of ZLN005. It acetylates PGC-1α at lysine residues, K277, K346, K359, 
K371, K373, K479 and K554(12). The first 5 lysine residues are located in the 
binding motifs for MYBBP1A (MYB-binding protein) which represses PGC-1α 
activity(182). Acetylation can affect protein stability, localization, and 
activity(12,178,182). It remains to be determined if acetylation of PGC-1α might alter 
its binding affinity for normal partner proteins and as a consequence its 
functionalities. As shown in Figure 5.2C, SR-18292 significantly increased PGC-
1α mRNA expression in primary human CD34+ derived erythroid cell cultures. 
SR-18292 at up to 10 µM did not have adverse effect upon cell viability in 
these erythroid cell cultures (Figure 5.2A and B). SR-18292 at 1, 5 and 10 µM 
significantly increased F-cell production in primary human CD34+ derived 
erythroid cell culture to ~30%, a level approaching to cultures treated with 25 µM 
hydroxyurea (Figure 5.2D and E), and also cultures treated with ZLN005 (Figure 
4.3E)  
SR-18292 had no statistically significant effect on the % of 
CD235a+/CD71+ cells. However, there was a delay in terminal differentiation, 





Additionally, SR-18292 did not statistically impact on the mRNA level of 6 
transcription factors known to regulate γ-globin gene expression (Figure 5.5).  
Similar to ZLN005, a combination of SR-18292 at 5 µM and hydroxyurea 
at 25 µM led to markedly elevated F-cell expression (60.2 ± 12.6%). SR-18292 at 
5 µM alone produced 33.6 ± 14.7%; while hydroxyurea at 25 µM alone produced 
36 ± 7.7% F-cells in these cultures (Figure 5.6A and B). This synergistic effect 
supports the notion that SR-18292 and hydroxyurea act to increase F-cells 
production through different pathways. 
PGC-1α is a coactivator that binds to other transcription factors(182). Post-
translational modifications of PGC-1α may alter its binding activity(182). 
Acetylation of PGC-1α by SR-18292 produced a delay in terminal differentiation, 
whereas phosphorylation of PGC-1α by ZLN005 did not affect terminal 
differentiation. It can be speculated that SR-18292 through acetylation alters the 
binding affinity of PGC-1α with its normal partner proteins and thereby changes 
its functionalities.  
A number of post-translational modifications, such as methylation, 
acetylation and phosphorylation, can induce PGC-1α mRNA expression as PGC-
1α has the ability to induce its own mRNA expression(11,193). Cui et al., (2015)(10) 
reported that lysine-specific demethylase (LSD1) inhibitor, RN1, upregulates 
PGC-1α mRNA expression(10). In recent report, in liver cell culture, PGC-1α at 
lysine residue K779 is dynamically methylated and demethylated by SET domain 





Methylated lysine residue K779 in PGC-1α appears to be coupled to enhancer 
RNA (eRNAs) which increases binding of Spt-Ada-Gcn5-acetyltransferase 
(SAGA) complex and thus enhances transcription of target genes(236). Loss of 
SET7/9 activity (i.e. methylation) leads to a diminished capacity of PGC-1α to 
maintain binding to the SAGA complex which in turn leads to loss of the ability of 
PGC-1α to stimulate transcription of target genes(236). Methylation of K779 could 
activate PGC-1α(236). It is possible that acetylation and phosphorylation work in a 
similar manner to methylation of PGC-1α in respect to recruitment of eRNAs and 
protein complexes, but the type of eRNAs or protein complex associated with 
phosphorylation and acetylation in erythroid cell system is still to be determined.  
In summary, these experiments show that SR-18292 can up-regulate 
PGC-1α in primary human erythroid cell cultures, and furthermore can increase 
F-cell production. Additionally, a combination of SR-18292 and hydroxyurea, 
leads to a highly significant synergistic effect upon F-cell production. These 
results together with those presented in Chapter IV on ZLN006 strongly advocate 
for the idea that combination therapy of hydroxyurea with a PGC-1α agonist such 
as SR-18292 or related compound might be efficacious for the treatment of SCD 







CHAPTER VI: An attempt to determine the effect of ZLN005 upon F-cell 
expression in vivo in a murine model of sickle cell disease 
6.1 INTRODUCTION  
In Chapter IV, it was shown that ZLN005 can increase F-cell production in 
primary human CD34+ derived erythroid cells in vitro. In this Chapter, attempt 
was made to replicate the ZLN005 effect in vivo. To that end, Townes SCD 
transgenic mice were used (mice strain is B6;129, Jackson laboratory # 013071). 
These mice are characterized by the replacement of their murine βmaj and βmin 
globin genes with human Aγ-globin (HBG1) and βS-globin genes(203,204) and 
murine α-globin genes with human α-globin gene (HBA1 only) (Figure 
6.1)(203,204).  
In this murine model, the regulation of human HBG1 expression mimics 
that of murine embryonic β-like globin genes (εy and βh1)(204). Furthermore, this 
transgenic mouse recapitulates the hematological effects of SCD in human, 







Figure 6.1. Wild type mouse α and β-globin genes and Townes sickle cell 
disease transgenic mouse α and β-globin genes structure 
A) The structure of β-globin locus located on chromosome 7 in normal mouse 
and Townes SCD transgenic mouse. The adult murine βmaj and βmin globin 
genes were replaced by the human Aγ-globin (HBG1) and β
S
-globin genes. In 
this mouse model the regulation of HBG1 mimic that of murine εy and βh1 globin 
genes. Arrows indicate the DNase hypersensitive sites that mark the locus 
control region (LCR). Red and yellow boxes indicate functional genes, white 
boxes indicate pseudogenes. B) The structure of α-globin locus located on 





human α1 (HBA1) gene. (Panel A was adopted and modified from Wu et al., 
2006(203). Panel B, not drawn to scale, drawn based on information from Rayn et 
al., 1997(204) and Vernimmen, 2014(238)).  
 
6.2 HYPOTHESIS 
ZLN005 is a PGC-1α agonist(11,196,223), and activates PGC-1α through the 
AMPK pathway(11) leading to phosphorylation of PGC-1α(196) at amino acid 
residues T178 and S539(229). Given that ZLN005 can increase F-cell expression 
in primary human CD34+ cell derived erythroid cell cultures in vitro, it is 
hypothesized that this compound can induce F-cell production in vivo in a 
transgenic murine model for sickle cell disease.  
 
6.3 GOALS 
1- To assess the optimal route of delivery of ZLN005 to mice. 
2- To ascertain if ZLN005 can induce F-cell expression in transgenic SCD 
mice in vivo.  
3- To determine the effect of ZLN005 on erythroid cell differentiation and 










6.4.1 To assess the optimal route of delivery of ZLN005 to mice. 
ZLN005 is a benzimidazole compound with poor aqueous solubility, poor 
oral bioavailability and with a short half-life in vivo(239). Due to the poor aqueous 
solubility of ZLN005, it was resuspended in 2-hydroxypropyl-β-cyclodextrin (HP-
β-CD), which is a cyclic oligosaccharide that improves the solubility of organic 
compounds with a phenyl group(201,202) (Figure 6.2).  
Figure 6.2. Structure of 2-hydroxypropyl-β-cyclodextrin. 
2-Hydroxypropyl-β-cyclodextrin is a cyclic oligosaccharide containing seven D (+) 
glucopyranose units. The arrangement of these sugar molecules creates a 
hollow, nonpolar, hydrophobic interior and a hydrophilic exterior. Such a structure 
allows hydrophobic compounds such as ZLN005 to occupy the interior cavity, 
thus improving their solubility (Adopted and redrawn from Katageri and Sheikh, 
2012(240)). 
 Initially, ZLN005 was injected intraperitoneally into adult transgenic mice at 





Subsequently, ZLN005 at 10 µg/g was injected intravenously daily through the 
tail vein. This caused progressive necrosis of the tail and these experiments had 
to be terminated at 2 weeks’ time. In the end, ZLN005 at 1 µg/g body weight was 
injected intravenously daily through the tail vein for 4 weeks, and the animals 
appeared to tolerate this procedure. In the control group, HP-β-CD solution 
without the ZLN005 was used as a vehicle control. Blood was collected via tail 
vein at 2 and 4 weeks for testing as described in Chapter II, Section 2.8. 
 
6.4.2 Effect of ZLN005 upon F-cell expression in SCD transgenic mouse.  
Figure 6.3 shows the expression of PGC-1α mRNA, globin mRNA and F-
cells in the peripheral blood of the SCD transgenic mice after they were treated 
with 1µg/g and 10µg/g ZLN005 for two weeks. There was no statistically 
significant difference in PGC-1α, murine embryonic εy, βh1, human HBG and 
HBB mRNA expressions, as determined by RT-qPCR, between the vehicle 
control and the 1 µg/g and 10 µg/g ZLN005 treated groups. Additionally, there 
was no statistically significant difference between the groups in the % F-cells as 






Figure 6.3. Murine PGC-1α mRNA, globin mRNA and F-cells expression in 
SCD transgenic mouse after 2 weeks treatment with ZLN005. 
A) Murine PGC-1α mRNA levels as determined by RT-qPCR obtained from SCD 
transgenic mice peripheral blood cells after treatment with 1 µg/g and 10 µg/g 
ZLN005 for 2 weeks. There was no statistically significant difference between the 
1 µg/g and 10 µg/g ZLN005 treated groups (1±0.3-fold and 1.2±0.5-fold, 
respectively) and the vehicle control group. B) The expression of εy, βh1, and γ 
and β-globin mRNAs determined by RT-qPCR. There was no statistically 
significant difference between 1 µg/g and 10 µg/g ZLN005 in εy (1.3±0.1 and 
1.4±0.1, respectively), βh1 (1.4±0.9 and 2.1±1, respectively), γ-globin (0.9±0.1-
fold and 1.3±0.1-fold, respectively) and β-globin (0.8±0.1-fold and 0.9±0.3-fold, 
respectively) mRNA expression compared to the vehicle control group. C) Flow 





vehicle control group (2.7%), 1 µg/g ZLN005 and 10 µg/g ZLN005 groups (3.8% 
and 3.4%, respectively). D) Summary of flow cytometry data of F-cells generated 
from the vehicle control group, 1 and 10 µg/g ZLN005 treated groups. There was 
no statistically significant difference in F-cells % between the 1 and 10 µg/g 
ZLN005 treated groups (4.3±0.3% and 3.3±0.6, respectively) and the vehicle 
control group (3.7±0.3%) (N=3 mice in each group). NS; not statistically 
significant. (C); Vehicle control. (Z1); 1 µg/g ZLN005. (Z10); 10 µg/g ZLN005.  
 
The same analysis was conducted on the peripheral blood taken after 4 
weeks from the vehicle control and ZLN005 at 1µg/g treated mice. Again, there 
was no statistically significant difference across all parameters with the exception 
of murine embryonic βh1 mRNA expression which showed a significant increase 
(7.8 ± 0.47-fold) in the 1 µg/g ZLN005 treated group when compared to the 














Figure 6.4. Murine PGC-1α mRNA, globin mRNA and F-cells expression in 
SCD transgenic mouse after 4 weeks treatment with ZLN005. 
A) Murine PGC-1α mRNA levels as determined by RT-qPCR obtained from SCD 
transgenic mice peripheral blood cells after treatment with 1 µg/g ZLN005 for 4 
weeks. There was no statistically significant difference between the 1 µg/g 
ZLN005 treated group (0.9±0.3-fold) and the vehicle control group. B) The 
expression of εy, βh1, and γ and β-globin mRNAs determined by RT-qPCR. 
There was no statistically significant difference between 1 µg/g ZLN005 in εy 
(1.1±0.4-folds), γ-globin (1.4±0.2-fold) and β-globin (1±0.2-fold) mRNA 
expression compared to the vehicle control group. However, there was a 
statistically significant increase in βh1 mRNA expression in the group treated with 
1 µg/g ZLN005 (7.8 ± 0.47-fold) compared to the vehicle control group C) Flow 





vehicle control group (4.1%), 1 µg/g ZLN005 treated mice groups (3.8%). D) 
Summary of flow cytometry data of % F-cells generated from the vehicle control 
group and the 1 µg/g ZLN005 treated group. There was no statistically significant 
difference in F-cell % between the 1 µg/g ZLN005 treated group (4 ± 0.6%) and 
the vehicle control group (3.7±0.2%) (N=3 mice in each group). NS; not 
statistically significant. (C); Vehicle control. (Z1); 1 µg/g ZLN005. P-values: 
*=0.00001  
 
6.4.3 The effect of ZLN005 on erythroid cell differentiation and 
reticulocytosis in SCD transgenic mice 
Peripheral blood erythroid cellular differentiation markers (Ter119/CD71) 
and reticulocyte % were determined using flow cytometry in cells obtained from 
mice peripheral blood from the vehicle control, 1 and 10 µg/g ZLN005 treated 
groups. There was no statistically significant difference across in these 
parameters between the 1 and 10 µg/g ZLN005 treated groups and the vehicle 
control group at 2 weeks (Figure 6.5) and between 1 µg/g ZLN005 treated group 






Figure 6.5. SCD transgenic mice peripheral blood Ter119/CD71 cells and 
reticulocyte % after 2 weeks of treatment with ZLN005. 
A) Flow cytometry profiles of a representative experiment showing peripheral 
blood stained with thiozole orange indicating reticulocyte % in the vehicle control 
(48.3%), 1 µg/g ZLN005 (57.5%) and 10 µg/g ZLN005 (59%) treated groups. B) 
Summary of flow cytometry data of reticulocyte % generated from the vehicle 
control group and the 1 and 10 µg/g ZLN005 treated groups. There was no 
statistically significant difference between the 1 and 10 µg/g ZLN005 treated 
groups (59.4 ± 5.9 % and 62.7 ± 1.3%, respectively) and the vehicle control 
group (51.4 ± 8.9%). C) Flow cytometry profiles of a representative experiment 
showing peripheral blood from the vehicle control group and the 1 and 10 µg/g 
ZLN005 treated groups, all stained with APC-labeled Ter119 antibodies and 









cells in the vehicle control group and the 1 and 10 µg/g ZLN005 treated groups. 




 cells between 
the 1 and 10 µg/g ZLN005 treated groups (85.1 ± 0.7% and 89.5 ± 1.2%) 
compared to the vehicle control group (87.1 ± 1.3%). (N=3 mice in each group). 
NS; not statistically significant. (C); Vehicle control. (Z1); 1 µg/g ZLN005. (Z10); 













Figure 6.6. Sickle cell disease transgenic mice peripheral blood 
Ter119/CD71 cells and reticulocyte % after 4 weeks treatment with ZLN005. 
A) Flow cytometry profiles of a representative experiment showing peripheral 
blood stained with thiozole orange indicating reticulocyte %in the vehicle control 
group (52.4%) and the 1 µg/g ZLN005 (57.5%) treated group. B) Summary of 
flow cytometry data of reticulocyte %generated from the vehicle control group 
and the 1 µg/g ZLN005 treated group. There was no statistically significant 
difference in reticulocyte % when comparing 1 µg/g ZLN005 treatment groups 
(51.7 ± 4.1) to vehicle control group (47.6 ± 3.6%). C) Flow cytometry profiles of 
a representative experiment showing peripheral blood from the vehicle control 
group and the 1 µg/g ZLN005 treated groups stained with APC-labeled Ter119 















between the 1 µg/g ZLN005 treated group (88.2 ± 1.6%) when compared with the 
vehicle control group (85.6 ± 3.1%). (N=3 mice in each group). NS; not 
statistically significant. (C); Vehicle control. (Z1); 1 µg/g ZLN005.  
 
6.5 DISCUSSION 
The in vivo experiments with ZLN005 in SCD transgenic mice were 
challenging due to its low aqueous solubility and instability. HP-β-CD was used to 
help improve its solubility. The results of these experiments showed that ZLN005 
had apparently no effect upon murine PGC-1α expression and human F-cell 
expression, erythroid cell differentiation and reticulocytosis. Since this compound 
was lethal to mice when injected intraperitoneally and caused tissue necrosis 
when given intravenously through the tail vein, it is critically important to 
ascertain that a sufficient amount of ZLN005 or its metabolites could be found in 
circulation before any definitive conclusion can be made regarding its potential in 
vivo effect upon F-cell expression. This was not done. Nevertheless, the 
observation that endogenous murine embryonic βh1 globin gene was 
upregulated after treatment of the mice with 1 µg/g ZLN005 for 4 weeks (Figure 
6.4B) might indicate that this compound indeed can increase embryonic/fetal 






The toxicity and solubility of ZLN005 present significant barriers to further 
experimentation. Alternatively, a subcutaneous injection could be used which 
would lead to slow release of the drug into the circulation. It will require checking, 
by mass spectrometry for example, to ensure that the drug is released into the 
mouse blood. In addition, SR-18292 shares a similar structure with ZLN005 and 
can enhance F-cell expression in vitro (Chapter 5). SR-18292 is more soluble in 
water than ZLN005. It can be resuspended in 10% DMSO, 10% tween80 and 
80% PBS solution for intraperitoneal injection(12).  
Sun et al., (2018)(239) identified phase I metabolites of ZLN005 which 
include those that are dihydroxylated on the tert-butyl group and the 5-position of 
the benzimidazole ring(239) and those that have one of the methyl groups of the 
tert-butyl group oxidized to a carboxylic group (Figure 6.7)(239). Dihydroxylation 
and carboxylation render the compound more soluble in aqueous solutions. 
Whether these metabolites possess similar biological functionalities as the parent 
compound remains to be investigated. Testing these ZLN005 metabolites in SCD 
transgenic mice is another avenue for future research.  
Lastly, consultation with medicinal biochemists with appropriate modeling 
might yield other compounds related to ZLN005 with similar effect upon HbF 







Figure 6.7. Phase 1 metabolites of ZLN005 
Dihydroxylation of the tert-butyl and the 5-position of benzimidazole 
groups is one product of phase 1 metabolites. Oxidation of one of the methyl 
groups of the tert-butyl group to carboxylic group is another product of phase I 
metabolism. Both products are more soluble than the ZLN005 compound and 
were found in rat plasma but whether they are biologically functional is unknown. 












CHAPTER VII: Summary and future direction 
7.1 Sickle cell disease and HbF  
SCD is a monogenic disorder with multi-organ involvement due to 
complex vasculopathy(1,5). Patients with SCD suffer from recurrent episodes of 
vaso occlusive crises (VOC) precipitated by deoxy-HbS polymerization leading to 
erythrocyte sickling(2). Increased HbF levels can ameliorate disease 
severity(105,108). The rate of HbS polymerization is inversely proportional to the 
HbF concentration(36). However, even patients with a high HbF level can have 
severe SCD phenotype. This can be attributed to the fact that HbF is unevenly 
distributed among F-cells, and the majority of cells have insufficient HbF 
concentrations to inhibit deoxy-HbS polymerization(108,241). Therefore, in order to 
protect against polymerization, the HbF concentration in F-cells must reach a 
specific value(108). It has been suggested that 10 pg of HbF in F-cells is sufficient 
to inhibit HbS polymerization(108). Recently, three drugs have been approved for 
SCD treatment: L-glutamine(7), crizanlizumab (monoclonal antibody that targets 
P-selectin)(167) and voxelotor (anti-sickling agent)(168). However, hydroxyurea is 
the only FDA-approved drug for the management of SCD known to induce HbF 
synthesis through a multifactorial mechanism(4). The HbF response to 
hydroxyurea is variable(108) and approximately 5-15% of patients show no 
significant clinical improvement(8). The cause of treatment failure is unclear(8,242). 






Therefore, it is important to identify new therapeutic agents that can 
induce HbF synthesis, preferably those that act by mechanisms different from 
hydroxyurea so as to allow possible combination therapy.  
Various transcription factors, such as BCL11A, KLF1, ZBTB7A, DNMT1 
and LSD1 have been found to regulate hemoglobin gene expression(4,10,124,132-
134,136,143,174). Cui et al., (2015)(10) reported that transduction with PGC-1α 
expression adenovirus in Lin– progenitor cells, isolated from bone marrow in 6-9 
week-old transgenic SCD mice (Townes model)(10), and induced into terminal 
erythroid differentiation in vitro, showed significant induction of γ-globin mRNA 
(4-fold and 6-fold increase, on Days 2 and 4, post-transduction, respectively) 
when compared to cultures transduced with GFP adenovirus(10). This indicate 
that PGC-1α is a potential new target for hemoglobin regulation.  
In the present work, I have shown for the first time that PGC-1α 
overexpression will significantly upregulate γ-globin mRNA expression in primary 
human CD34+ derived erythroid cell culture, thereby leading to increased F-cell 
expression (~40%) (Chapter 3). Consequently, it can be hypothesized that PGC-
1α is a novel therapeutic target to increase HbF synthesis. The main focus of this 







7.2 PGC-1α agonists 
 The focus of this work was on the identification of small molecules that 
could induce PGC-1α and in turn increase F-cells % in primary human CD34+ 
derived erythroid cells. This quest resulted in the identification of two small 
molecules, ZLN005 and SR-18292, that could induce F-cells % to a level 
comparable to that found when hydroxyurea is used. Both induce PGC-1α mRNA 
expression in primary human CD34+ derived erythroid cell culture. In addition, 
both compounds can mediate post-translational modification of PGC-1α in 
hepatocytes (12,196). Further research is needed to ascertain if there is a role of 
PGC-1α post-translational modification by ZLN005 and SR-18292 in hemoglobin 
regulation.  
ZLN005 at a concentration of 1 µM, can up-regulate PGC-1α mRNA 
expression in primary human erythroid cells to a level that is 4-fold of the control 
(Chapter 4). The activation of PGC-1α by ZLN005 is through the AMPK 
pathway(11), which ultimately leads to phosphorylation of human PGC-1α(196) at 
amino acid positions T178 and S539(229). Moreover, PGC-1α activation promotes 
an increase in its mRNA synthesis(11,193). Both of these mechanisms account for 
ZLN005 induction of PGC-1α mRNA expression without any effect on the 
expression of transcription factors and erythroid cell differentiation and terminal 
maturation. Moreover, the combination of ZLN005 and hydroxyurea had a 





produced ~20 to 30% F-cells (Figure 4.8). These observations are indicative that 
ZLN005 and hydroxyurea induce F-cells production by different mechanisms.  
The second small molecule identified was SR-18292 that acetylates PGC-
1α at lysine residues, K277, K346, K359, K371, K373, K479 and K554(12) 
(Chapter 5). The first 5 lysine residues are located in the binding motifs for 
MYBBP1A (MYB-binding protein). Binding of MYBBP1A to PGC-1α represses 
PGC-1α activity(182). Acetylation can affect protein stability, localization, and 
activity(12,178,182). It remains to be determined if acetylation of PGC-1α might alter 
its binding affinity for normal partner proteins and as a consequence, its 
functionalities. Moreover, the combination of SR-18292 and hydroxyurea had a 
synergistic effect on the induction of F-cells (~ 60%), while either drug alone 
produced ~30% F-cells indicating that each of these drugs works by a different 
mechanism to induce F-cells.  
 
7.3 Challenges faced using PGC-1α agonist in SCD murine model 
 One of the challenges in the use of ZLN005 in vivo in experimental 
animals, is its poor solubility and toxicity (Chapter 6). In future research, I 
propose the use of phase I metabolites (Figure 6.7). However, prior to their use, 
the biological activity of phase I metabolites needs to be determined. Perhaps 
testing them in primary human CD34+ derived erythroid cell culture is the first 





7.4 Future direction 
 This work has shown for the first time that PGC-1α can be modulated by 
small molecules to enhance production of F-cells. The next step is to conduct 
detailed protein analysis of PGC-1α in human erythroid cells to gain a better 
understanding on how post-translational modifications affect the activity of PGC-
1α and which transcription factors are associated with these modifications. PGC-
1α has more than 9 splice isoforms that have different binding motifs, leading to 
distinct functionalities(183,189). Alternative usage of promoters boosts the 
complexity of the transcriptome and produces several proteins from one 
individual gene(183). To date, it is not known what type of PGC-1α splicing 
isoforms exist in erythroid cells or if there are promoter regions that differ from 
the canonical promoters in the erythroid cell system. This could be illustrated 
through a targeted RNA-Seq to identify PGC-1α RNA splice isoforms in primary 
human CD34+ derived erythroid cells. RNA-Seq and mass spectrometry should 
be done together to get a complete picture of PGC-1α splice isoform in primary 
human CD34+ derived erythroid cells.  
I did not detect any effect of ZLN005 on F-cells induction when injected 
intravenously to SCD transgenic mice. This compound is highly hydrophobic and 
causes tissue necrosis. There are 8 other compounds (Figure 5.1) that can 
acetylate PGC-1α, and ZLN005 phase 1 metabolites (Figure 6.7). These would 
be potential candidates for future experimentation to induce F-cell production in 





In summary, two small molecules were identified, both PGC-1α agonists, 
which could up-regulate F-cell production in primary human CD34+ derived 
erythroid cell cultures in vitro. In combination with hydroxyurea, there was a 
significant synergistic effect. Future work will include 1) Identify related 
compounds with less toxicity, better aqueous solubility, and bioavailability, and 2) 
Undertake in vivo experiments in SCD mice to replicate the in vitro experimental 
results. These findings could provide proof of principle for combination therapy to 
treat SCD patients in order to ameliorate their disease severity by up-regulating 
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